Clinical diagnosis of progressive supranuclear palsy: Th criteria

Movement Disorders

32, 853-864

DOI: 10.1002/mds.26987

Citation Report

#	Article	IF	Citations
1	Differentiation of atypical Parkinson syndromes. Journal of Neural Transmission, 2017, 124, 997-1004.	1.4	30
2	Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. Movement Disorders, 2017, 32, 955-971.	2.2	179
3	Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials. Movement Disorders, 2017, 32, 842-852.	2.2	52
4	Reply to: MRI measures of brainstem in parkinsonian syndromes: Where we stand and where we need to go. Movement Disorders, 2017, 32, 1261-1262.	2.2	1
5	Therapeutic options for Progressive Supranuclear Palsy including investigational drugs. Expert Opinion on Orphan Drugs, 2017, 5, 575-587.	0.5	5
6	Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurology, The, 2017, 16, 552-563.	4.9	303
7	Genetic influences on cognition in progressive supranuclear palsy. Movement Disorders, 2017, 32, 1764-1771.	2.2	6
8	Natural history and predictors of survival in progressive supranuclear palsy. Journal of the Neurological Sciences, 2017, 382, 105-107.	0.3	32
9	¹⁸Fâ€flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. Annals of Neurology, 2017, 82, 622-634.	2.8	148
10	Cognitive impairment in progressive supranuclear palsy is associated with tau burden. Movement Disorders, 2017, 32, 1772-1779.	2.2	46
11	Tau Diagnostics and Clinical Studies. Journal of Molecular Neuroscience, 2017, 63, 123-130.	1.1	11
12	Update on tauopathies. Current Opinion in Neurology, 2017, 30, 589-598.	1.8	54
13	¹⁸F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment. Journal of Nuclear Medicine, 2017, 58, 1888-1898.	2.8	139
14	Optical coherence tomography identifies outer retina thinning in frontotemporal degeneration. Neurology, 2017, 89, 1604-1611.	1.5	39
15	Mild Cognitive Impairment and Progression to Dementia in Progressive Supranuclear Palsy. Neurodegenerative Diseases, 2017, 17, 286-291.	0.8	30
16	6-OHDA-Lesioned Adult Zebrafish as a Useful Parkinsonâ€™s Disease Model for Dopaminergic Neuroregeneration. Neurotoxicity Research, 2017, 32, 496-508.	1.3	40
17	Regional microstructural damage and patterns of eye movement impairment: a DTI and video-oculography study in neurodegenerative parkinsonian syndromes. Journal of Neurology, 2017, 264, 1919-1928.	1.8	13
18	Emerging Diagnostic and Therapeutic Strategies for Tauopathies. Current Neurology and Neuroscience Reports, 2017, 17, 72.	2.0	31

#	Article	IF	Citations
19	Nonmotor Features in Atypical Parkinsonism. International Review of Neurobiology, 2017, 134, 1285-1301.	0.9	21
20	A clinicopathological approach to the diagnosis of dementia. Nature Reviews Neurology, 2017, 13, 457-476.	4.9	233
21	Imaging tau pathology in Parkinsonisms. Npj Parkinson's Disease, 2017, 3, 22.	2.5	13
22	Sleepless Night and Day, the Plight of Progressive Supranuclear Palsy. Sleep, 2017, 40, .	0.6	35
23	Aphasia in Progressive Supranuclear Palsy: As Severe as Progressive Non-Fluent Aphasia. Journal of Alzheimer's Disease, 2017, 61, 705-715.	1.2	20
24	In the Pipeline-Progressive Supranuclear Palsy. Neurology Today: an Official Publication of the American Academy of Neurology, 2017, 17, 36-39.	0.0	0
26	Progressive supranuclear palsy and idiopathic Parkinsonâ€™s disease are associated with local reduction of in vivo brain viscoelasticity. European Radiology, 2018, 28, 3347-3354.	2.3	31
27	Pearls & Oy-sters: Ocular motor apraxia as essential differential diagnosis to supranuclear gaze palsy. Neurology, 2018, 90, 482-485.	1.5	10
28	Progressive spasticity, supranuclear gaze palsy and postural instability, without parkinsonism: whatâ€™s in a phenotype?. Journal of the Neurological Sciences, 2018, 390, 84-86.	0.3	1
29	The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. Parkinsonism and Related Disorders, 2018, 54, 90-94.	1.1	49
31	Progressive Supranuclear Palsy: an Update. Current Neurology and Neuroscience Reports, 2018, 18, 12.	2.0	59
32	White matter change with apathy and impulsivity in frontotemporal lobar degeneration syndromes. Neurology, 2018, 90, e1066-e1076.	1.5	31
33	Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. Alzheimer's and Dementia, 2018, 14, 751-763.	0.4	61
34	Diagnostic potential of dentatorubrothalamic tract analysis in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2018, 49, 81-87.	1.1	27
35	The Role of Rehabilitation in Patients With Progressive Supranuclear Palsy: A Narrative Review. PM and R, 2018, 10, 636-645.	0.9	13
36	Neurotransmitter deficits from frontotemporal lobar degeneration. Brain, 2018, 141, 1263-1285.	3.7	129
37	Tracking brain damage in progressive supranuclear palsy: a longitudinal MRI study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 696-701.	0.9	18
38	CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology, 2018, 90, e273-e281.	1.5	75

#	Article	IF	Citations
39	Is it Useful to Classify Progressive Supranuclear Palsy and Corticobasal Degeneration as Different Disorders? No. Movement Disorders Clinical Practice, 2018, 5, 141-144.	0.8	28
40	Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2018, 48, 3-9.	1.1	27
41	Is it Useful to Classify PSP and CBD as Different Disorders? Yes. Movement Disorders Clinical Practice, 2018, 5, 145-148.	0.8	18
42	Tau burden and the functional connectome in Alzheimerâ€™s disease and progressive supranuclear palsy. Brain, 2018, 141, 550-567.	3.7	190
43	Tau Imaging in Parkinsonism: What Have We Learned So Far?. Movement Disorders Clinical Practice, 2018, 5, 118-130.	0.8	14
44	Progression of white matter damage in progressive supranuclear palsy with predominant parkinsonism. Parkinsonism and Related Disorders, 2018, 49, 95-99.	1.1	13
45	Urinary Dysfunctions and Post-Void Residual Urine in Typical and Atypical Parkinson Diseases. Journal of Parkinson's Disease, 2018, 8, 145-152.	1.5	10
46	Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1470-1486.	3.3	19
47	[¹¹ C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy. Neurology, 2018, 90, e1989-e1996.	1.5	89
48	Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathologica, 2018, 136, 363-376.	3.9	114
49	Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy. Expert Opinion on Investigational Drugs, 2018, 27, 349-361.	1.9	20
50	Disrupted functional connectivity in primary progressive apraxia of speech. NeuroImage: Clinical, 2018, 18, 617-629.	1.4	36
51	Levodopa-induced dystonia in a patient with possible progressive supranuclear palsy with progressive gait freezing. Journal of the Neurological Sciences, 2018, 388, 139-140.	0.3	1
52	A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes. JAMA Neurology, 2018, 75, 738.	4.5	54
53	Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology. Brain, 2018, 141, 13-36.	3.7	145
54	The diagnosis of dementias: a practical tool not to miss rare causes. Neurological Sciences, 2018, 39, 615-627.	0.9	14
55	Beyond ALS and FTD: the phenotypic spectrum of TBK1 mutations includes PSP-like and cerebellar phenotypes. Neurobiology of Aging, 2018, 62, 244.e9-244.e13.	1.5	30
56	Prominent Tongue and Jaw Tremor in a Patient with Probable Progressive Supranuclear Palsy. Movement Disorders Clinical Practice, 2018, 5, 99-100.	0.8	4

#	Article	IF	Citations
57	MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSP. Parkinsonism and Related Disorders, 2018, 46, 47-55.	1.1	45
58	Atypical parkinsonian syndromes: a general neurologist's perspective. European Journal of Neurology, 2018, 25, 41-58.	1.7	46
60	Chronic meningoencephalitis with mixed pathology mimics progressive supranuclear palsy. BMJ Case Reports, 2018, 11, e227119.	0.2	2
61	Neuropsychiatric disturbances in atypical parkinsonian disorders. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2643-2656.	1.0	21
62	The DÃ©pistage Cognitif de QuÃ©bec: A New Clinicianâ€™s Tool for Early Recognition of Atypical Dementia. Dementia and Geriatric Cognitive Disorders, 2018, 46, 310-321.	0.7	13
63	Cervical skin denervation associates with alphaâ€synuclein aggregates in Parkinson disease. Annals of Clinical and Translational Neurology, 2018, 5, 1394-1407.	1.7	39
64	The Luxembourg Parkinsonâ€™s Study: A Comprehensive Approach for Stratification and Early Diagnosis. Frontiers in Aging Neuroscience, 2018, 10, 326.	1.7	57
65	Stereotypic behaviours in frontotemporal dementia and progressive supranuclear palsy. Cortex, 2018, 109, 272-278.	1.1	4
66	Visual Search in Progressive Supranuclear Palsy. Current Topics in Behavioral Neurosciences, 2018, 41, 305-324.	0.8	4
67	CSF sAPPÎ², YKL-40, and NfL along the ALS-FTD spectrum. Neurology, 2018, 91, e1619-e1628.	1.5	59
68	The Role of Tau Imaging in Parkinsonian Disorders. Current Neurology and Neuroscience Reports, 2018, 18, 86.	2.0	14
69	Clinical Progression in Four Cases of Primary Progressive Apraxia of Speech. American Journal of Speech-Language Pathology, 2018, 27, 1303-1318.	0.9	36
70	Verbal adynamia in parkinsonian syndromes: behavioral correlates and neuroanatomical substrate. Neurocase, 2018, 24, 204-212.	0.2	19
71	Tau PET imaging evidence in patients with cognitive impairment: preparing for clinical use. Clinical and Translational Imaging, 2018, 6, 471-482.	1.1	3
72	Functional MRI in Atypical Parkinsonisms. International Review of Neurobiology, 2018, 142, 149-173.	0.9	11
73	Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study. Journal of Alzheimer's Disease, 2018, 66, 551-563.	1.2	46
74	Systematic review of movement disorders and oculomotor abnormalities in Whipple's disease. Movement Disorders, 2018, 33, 1700-1711.	2.2	25
75	PET Molecular Imaging in Atypical Parkinsonism. International Review of Neurobiology, 2018, 142, 3-36.	0.9	8

#	Article	IF	Citations
76	Is the Latency from Progressive Supranuclear Palsy Onset to Diagnosis Improving?. Movement Disorders Clinical Practice, 2018, 5, 603-606.	0.8	31
77	Comparative cognitive and neuropsychiatric profiles between Parkinsonâ€™s disease, multiple system atrophy and progressive supranuclear palsy. Journal of Neurology, 2018, 265, 2602-2613.	1.8	80
78	Diagnostic challenges in multiple system atrophy. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 179-184.	1.0	4
79	Clinical, Anatomical, and Pathological Features in the Three Variants of Primary Progressive Aphasia: A Review. Frontiers in Neurology, 2018, 9, 692.	1.1	106
80	Diagnostic challenges in rapidly progressive dementia. Expert Review of Neurotherapeutics, 2018, 18, 761-772.	1.4	29
81	Diagnosis of PSP-P: Can a newly developed MRPI make the difference?. Parkinsonism and Related Disorders, 2018, 54, 1-2.	1.1	1
82	Subtle Esophageal Motility Alterations in Parkinsonian Syndromes: Synucleinopathies vs. Tauopathies. Movement Disorders Clinical Practice, 2018, 5, 406-412.	0.8	13
83	Blink reflex recovery cycle to differentiate progressive supranuclear palsy from corticobasal syndrome. European Journal of Neurology, 2018, 25, 1100.	1.7	5
84	The Sleep Disorder in Anti-lgLON5 Disease. Current Neurology and Neuroscience Reports, 2018, 18, 41.	2.0	42
85	Clinical utility of FDG PET in Parkinsonâ€™s disease and atypical parkinsonism associated with dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1534-1545.	3.3	86
86	Other Major and Mild Neurocognitive Disorders: Parkinson Disease, Atypical Parkinsonism, and Traumatic Brain Injury Types. , 2018, , 243-268.		0
87	Semi-quantitative dopamine transporter standardized uptake value in comparison with conventional specific binding ratio in [123I] FP-CIT single-photon emission computed tomography (DaTscan). Neurological Sciences, 2018, 39, 1401-1407.	0.9	3
88	Will FTLD-tau work for all when FTDP-17 retires?. Brain, 2018, 141, e62-e62.	3.7	2
89	European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain ¹⁸Fâ€fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. European Journal of Neurology, 2018, 25, 1201-1217.	1.7	153
90	Therapeutic Management of the Overlapping Syndromes of Atypical Parkinsonism. CNS Drugs, 2018, 32, 827-837.	2.7	16
91	Epigenome-wide DNA methylation profiling in Progressive Supranuclear Palsy reveals major changes at DLX1. Nature Communications, 2018, 9, 2929.	5.8	20
92	Parkinsonâ€™s Disease Diagnostic Observations (PADDO): study rationale and design of a prospective cohort study for early differentiation of parkinsonism. BMC Neurology, 2018, 18, 69.	0.8	7
93	A new MR imaging index for differentiation of progressive supranuclear palsy-parkinsonism from Parkinson's disease. Parkinsonism and Related Disorders, 2018, 54, 3-8.	1.1	98

#	Article	IF	Citations
94	Neurophysiological signatures of Alzheimerâ€™s disease and frontotemporal lobar degeneration: pathology versus phenotype. Brain, 2018, 141, 2500-2510.	3.7	60
95	Variation at the TRIM11 locus modifies progressive supranuclear palsy phenotype. Annals of Neurology, 2018, 84, 485-496.	2.8	37
97	Plasma Biomarkers Differentiate Parkinsonâ€™s Disease From Atypical Parkinsonism Syndromes. Frontiers in Aging Neuroscience, 2018, 10, 123.	1.7	43
98	Role of Neuroimaging as a Biomarker for Neurodegenerative Diseases. Frontiers in Neurology, 2018, 9, 265.	1.1	32
99	Structural and Functional Brain Mapping Correlates of Impaired Eye Movement Control in Parkinsonian Syndromes: A Systems-Based Concept. Frontiers in Neurology, 2018, 9, 319.	1.1	9
100	Clinical Routine FDG-PET Imaging of Suspected Progressive Supranuclear Palsy and Corticobasal Degeneration: A Gatekeeper for Subsequent Tau-PET Imaging?. Frontiers in Neurology, 2018, 9, 483.	1.1	21
101	Primary progressive freezing gait with impressive response to laser light visual cueing: a video case report. Journal of Neurology, 2018, 265, 2146-2148.	1.8	1
102	MDS PSP criteria in realâ€life clinical setting: Motor and cognitive characterization of subtypes. Movement Disorders, 2018, 33, 1361-1365.	2.2	24
103	MRI-based neuroimaging: atypical parkinsonisms and other movement disorders. Current Opinion in Neurology, 2018, 31, 425-430.	1.8	15
104	Difficulties in the diagnosis of four repeats (4R) tauopathic parkinsonian syndromes. Neurologia I Neurochirurgia Polska, 2018, 52, 459-464.	0.6	9
105	Unusual Clinical Presentations Challenging the Early Clinical Diagnosis of Creutzfeldt-Jakob Disease. Journal of Alzheimer's Disease, 2018, 64, 1051-1065.	1.2	34
106	Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1509-1525.	3.3	81
107	The neuroanatomical and neurochemical basis of apathy and impulsivity in frontotemporal lobar degeneration. Current Opinion in Behavioral Sciences, 2018, 22, 14-20.	2.0	54
108	The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. Alzheimer's Research and Therapy, 2018, 10, 3.	3.0	76
109	The role of 18F-FP-CIT PET in differentiation of progressive supranuclear palsy and frontotemporal dementia in the early stage. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1585-1595.	3.3	20
110	Progressive supranuclear palsy and multiple system atrophy: clinicopathological concepts and therapeutic challenges. Current Opinion in Neurology, 2018, 31, 448-454.	1.8	19
111	New classification of tauopathies. Revue Neurologique, 2018, 174, 664-668.	0.6	39
112	Tauopathy-Associated PERK Alleles are Functional Hypomorphs that Increase Neuronal Vulnerability to ER Stress. Human Molecular Genetics, 2018, 27, 3951-3963.	1.4	36

#	Article	IF	Citations
113	Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy. Journal of Neural Transmission, 2018, 125, 1373-1379.	1.4	25
114	The diagnosis of progressive supranuclear palsy: current opinions and challenges. Expert Review of Neurotherapeutics, 2018, 18, 603-616.	1.4	18
115	Clinical and imaging progression over 10 years in a patient with primary progressive apraxia of speech and autopsy-confirmed corticobasal degeneration. Neurocase, 2018, 24, 111-120.	0.2	25
116	Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. Acta Neuropathologica, 2018, 136, 389-404.	3.9	59
117	PSP-Phenotype in SCA8: Case Report and Systemic Review. Cerebellum, 2019, 18, 76-84.	1.4	11
118	Long-term treatment with rotigotine in drug-naÃ¯ve PSP patients. Acta Neurologica Belgica, 2019, 119, 113-116.	0.5	3
119	Association between semantic dementia and progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 115-117.	0.9	6
121	Sensitivity and specificity of diagnostic criteria for progressive supranuclear palsy. Movement Disorders, 2019, 34, 1087-1088.	2.2	2
122	Advances in Management of Neuropsychiatric Syndromes in Neurodegenerative Diseases. Current Psychiatry Reports, 2019, 21, 79.	2.1	38
123	Diagnostic validity of magnetic resonance parkinsonism index in differentiating patients with progressive supranuclear palsy from patients with Parkinson's disease. Parkinsonism and Related Disorders, 2019, 66, 176-181.	1.1	15
124	Efficient RT-QuIC seeding activity for Î±-synuclein in olfactory mucosa samples of patients with Parkinsonâ€™s disease and multiple system atrophy. Translational Neurodegeneration, 2019, 8, 24.	3.6	106
125	Cerebellar rTMS for motor control in progressive supranuclear palsy. Brain Stimulation, 2019, 12, 1588-1591.	0.7	16
126	Characteristics and progression of cognitive deficits in progressive supranuclear palsy vs. multiple system atrophy and Parkinsonâ€™s disease. Journal of Neural Transmission, 2019, 126, 1437-1445.	1.4	25
127	The combination of short-step and wide-based gait is a gait characteristic in progressive supranuclear palsy: a retrospective, cross-sectional study. European Geriatric Medicine, 2019, 10, 809-815.	1.2	3
128	How to spot ocular abnormalities in progressive supranuclear palsy? A practical review. Translational Neurodegeneration, 2019, 8, 20.	3.6	17
129	Progression of two Progressive Supranuclear Palsy phenotypes with comparable initial disability. Parkinsonism and Related Disorders, 2019, 66, 87-93.	1.1	21
130	The genetic and clinicoâ€pathological profile of earlyâ€onset progressive supranuclear palsy. Movement Disorders, 2019, 34, 1307-1314.	2.2	16
131	Severe Constipation in Parkinson's Disease and in Parkinsonisms: Prevalence and Affecting Factors. Frontiers in Neurology, 2019, 10, 621.	1.1	25

#	Article	IF	Citations
132	One decade ago, one decade ahead in progressive supranuclear palsy. Movement Disorders, 2019, 34, 1284-1293.	2.2	12
133	Multimodal neuroimaging relationships in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2019, 66, 56-61.	1.1	19
134	Improving diagnostic accuracy of multiple system atrophy: a clinicopathological study. Brain, 2019, 142, 2813-2827.	3.7	121
135	Midbrain atrophy in patients with presymptomatic progressive supranuclear palsy-Richardson's syndrome. Parkinsonism and Related Disorders, 2019, 66, 80-86.	1.1	11
136	Co-morbidity of progressive supranuclear palsy and amyotrophic lateral sclerosis: a clinical-pathological case report. BMC Neurology, 2019, 19, 168.	0.8	10
137	Dystonia in atypical parkinsonian disorders. Parkinsonism and Related Disorders, 2019, 66, 25-33.	1.1	25
138	Are PSP patients included in clinical trials representative of the general PSP population?. Parkinsonism and Related Disorders, 2019, 66, 202-206.	1.1	3
139	Posturographic abnormalities in ambulatory atypical parkinsonian disorders: Differentiating characteristics. Parkinsonism and Related Disorders, 2019, 66, 94-99.	1.1	11
140	Validation of the Italian version of the PSP Quality of Life questionnaire. Neurological Sciences, 2019, 40, 2587-2594.	0.9	5
141	Recent Advancement and Clinical Implications of 18FDG-PET in Parkinsonâ€™s Disease, Atypical Parkinsonisms, and Other Movement Disorders. Current Neurology and Neuroscience Reports, 2019, 19, 56.	2.0	9
142	Coexistence of Progressive Supranuclear Palsy With Pontocerebellar Atrophy and Myotonic Dystrophy Type 1. Journal of Neuropathology and Experimental Neurology, 2019, 78, 756-762.	0.9	3
143	Potential usefulness of signal intensity of cerebral gyri on quantitative susceptibility mapping for discriminating corticobasal degeneration from progressive supranuclear palsy and Parkinsonâ€™s disease. Neuroradiology, 2019, 61, 1251-1259.	1.1	6
144	Diffusion Tensor MRI to Distinguish Progressive Supranuclear Palsy from Î±-Synucleinopathies. Radiology, 2019, 293, 646-653.	3.6	20
145	Transcranial sonography in atypical parkinsonism: How reliable is it in real clinical practice? A multicentre comprehensive study. Parkinsonism and Related Disorders, 2019, 68, 40-45.	1.1	13
146	Mutation analysis of LRP10 in Japanese patients with familial Parkinson's disease, progressive supranuclear palsy, and frontotemporal dementia. Neurobiology of Aging, 2019, 84, 235.e11-235.e16.	1.5	10
147	Clinical use of SAND battery to evaluate language in patients with Progressive Supranuclear Palsy. PLoS ONE, 2019, 14, e0223621.	1.1	12
148	Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?. Parkinsonism and Related Disorders, 2019, 69, 34-39.	1.1	18
149	Slowed vertical saccades as a hallmark of hereditary spastic paraplegia type 7. Annals of Clinical and Translational Neurology, 2019, 6, 2127-2132.	1.7	3

#	Article	IF	Citations
150	Progressive supranuclear palsy, multiple system atrophy and corticobasal degeneration. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 165, 155-177.	1.0	16
152	Frontrunner in Translation: Progressive Supranuclear Palsy. Frontiers in Neurology, 2019, 10, 1125.	1.1	19
153	Track density imaging: A reliable method to assess white matter changes in Progressive Supranuclear Palsy with predominant parkinsonism. Parkinsonism and Related Disorders, 2019, 69, 23-29.	1.1	4
154	Neuropathologic basis of frontotemporal dementia in progressive supranuclear palsy. Movement Disorders, 2019, 34, 1655-1662.	2.2	14
155	Progressive supranuclear palsy is not associated with neurogenic orthostatic hypotension. Neurology, 2019, 93, e1339-e1347.	1.5	16
156	Late-onset Niemannâ€“Pick disease type C overlapping with frontotemporal dementia syndromes: a case report. Journal of Neural Transmission, 2019, 126, 1501-1504.	1.4	7
157	Quantitative susceptibility mapping in atypical Parkinsonisms. NeuroImage: Clinical, 2019, 24, 101999.	1.4	49
158	PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes. Frontiers in Aging Neuroscience, 2019, 11, 249.	1.7	30
159	An update on genetic frontotemporal dementia. Journal of Neurology, 2019, 266, 2075-2086.	1.8	253
160	Impact of a combination of quantitative indices representing uptake intensity, shape, and asymmetry in DAT SPECT using machine learning: comparison of different volume of interest settings. EJNMMI Research, 2019, 9, 7.	1.1	13
161	Cellular and regional vulnerability in frontotemporal tauopathies. Acta Neuropathologica, 2019, 138, 705-727.	3.9	49
162	Validation of the Italian version of carersâ€™ quality-of-life questionnaire for parkinsonism (PQoL) Tj ETQq1 1 0.784314 rgBT /Overlock	0.9	5
163	Disrupted structural connectivity of fronto-deep gray matter pathways in progressive supranuclear palsy. NeuroImage: Clinical, 2019, 23, 101899.	1.4	11
164	Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. Brain, 2019, 142, 2466-2482.	3.7	33
165	Fronto-parietal contributions to episodic retrievalâ€”evidence from neurodegenerative disorders. Learning and Memory, 2019, 26, 262-271.	0.5	9
166	Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical updateâ€”I. Hypokinetic-rigid movement disorders. Journal of Neural Transmission, 2019, 126, 933-995.	1.4	28
167	â€œOne lineâ€: A method for differential diagnosis of parkinsonian syndromes. Acta Neurologica Scandinavica, 2019, 140, 229-235.	1.0	9
168	Four-repeat tauopathies. Progress in Neurobiology, 2019, 180, 101644.	2.8	141

#	Article	IF	Citations
169	Utility of the Movement Disorders Society Criteria for Progressive Supranuclear Palsy in Clinical Practice. Movement Disorders Clinical Practice, 2019, 6, 436-439.	0.8	10
170	Screening for Niemann-Pick type C disease in neurodegenerative diseases. Journal of Clinical Neuroscience, 2019, 68, 266-267.	0.8	2
171	Treatment of psychiatric disturbances in hypokinetic movement disorders. Expert Review of Neurotherapeutics, 2019, 19, 965-981.	1.4	8
172	An Evaluation of the Progressive Supranuclear Palsy Speech/Language Variant. Movement Disorders Clinical Practice, 2019, 6, 452-461.	0.8	26
173	A metabolic profile of polyamines in parkinson disease: A promising biomarker. Annals of Neurology, 2019, 86, 251-263.	2.8	74
174	Stimulation over the cerebellum with a regular figure-of-eight coil induces reduced motor cortex inhibition in patients with progressive supranuclear palsy. Brain Stimulation, 2019, 12, 1290-1297.	0.7	23
175	Increased prefrontal cortex interleukin-2 protein levels and shift in the peripheral T cell population in progressive supranuclear palsy patients. Scientific Reports, 2019, 9, 7781.	1.6	9
177	Functional movement disorders in neurogeriatric inpatients. Zeitschrift Fur Gerontologie Und Geriatrie, 2019, 52, 324-329.	0.8	10
178	Neuropathological correlates of structural and functional imaging biomarkers in 4-repeat tauopathies. Brain, 2019, 142, 2068-2081.	3.7	30
179	Dyskinesia in multiple system atrophy and progressive supranuclear palsy. Journal of Neural Transmission, 2019, 126, 925-932.	1.4	11
180	Emerging drugs for progressive supranuclear palsy. Expert Opinion on Emerging Drugs, 2019, 24, 83-92.	1.0	6
181	Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs. Expert Opinion on Pharmacotherapy, 2019, 20, 1091-1107.	0.9	15
182	Grand Total EEG Score Can Differentiate Parkinson's Disease From Parkinson-Related Disorders. Frontiers in Neurology, 2019, 10, 398.	1.1	14
183	Tau tubulin kinases in proteinopathy. FEBS Journal, 2019, 286, 2434-2446.	2.2	14
184	Classification of degenerative parkinsonism subtypes by support-vector-machine analysis and striatal 123I-FP-CIT indices. Journal of Neurology, 2019, 266, 1771-1781.	1.8	35
185	Motor, cognitive and behavioral differences in MDS PSP phenotypes. Journal of Neurology, 2019, 266, 1727-1735.	1.8	30
186	Persistent and Progressive Outer Retina Thinning in Frontotemporal Degeneration. Frontiers in Neuroscience, 2019, 13, 298.	1.4	17
187	Association of MAPT Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology. JAMA Neurology, 2019, 76, 710.	4.5	39

#	Article	IF	Citations
188	Asymmetric Limb Dystonia in Progressive Supranuclear Palsy: Conundrum in Nosology. Movement Disorders Clinical Practice, 2019, 6, 415-416.	0.8	1
189	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Movement Disorders, 2019, 34, 1228-1232.	2.2	93
190	Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 768-773.	0.9	29
191	Revisiting the Cerebrospinal Fluid Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus: The Bologna Pro-Hydro Study. Journal of Alzheimer's Disease, 2019, 68, 723-733.	1.2	21
192	Atrophy in midbrain & cerebral/cerebellar pedunculi is characteristic for progressive supranuclear palsy â€“ A double-validation whole-brain meta-analysis. NeuroImage: Clinical, 2019, 22, 101722.	1.4	22
193	Improved language production with transcranial direct current stimulation in progressive supranuclear palsy. Neuropsychologia, 2019, 127, 148-157.	0.7	27
194	Detection of Alzheimerâ€™s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau). Acta Neuropathologica Communications, 2019, 7, 34.	2.4	27
195	Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology, 2019, 92, e1479-e1486.	1.5	100
196	Tandem gait abnormality in Parkinson disease: Prevalence and implication as a predictor of fall risk. Parkinsonism and Related Disorders, 2019, 63, 83-87.	1.1	6
197	Prognostic importance of apathy in syndromes associated with frontotemporal lobar degeneration. Neurology, 2019, 92, e1547-e1557.	1.5	42
198	Precision Medicine for Frontotemporal Dementia. Frontiers in Psychiatry, 2019, 10, 75.	1.3	16
199	Accumulation of Tau Protein, Metabolism and Perfusionâ€”Application and Efficacy of Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) Imaging in the Examination of Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS). Frontiers in Neurology, 2019, 10, 101.	1.1	16
200	Pyramidal system involvement in progressive supranuclear palsy â€“ a clinicopathological correlation. BMC Neurology, 2019, 19, 42.	0.8	8
201	Disease-modifying therapies for tauopathies: agents in the pipeline. Expert Review of Neurotherapeutics, 2019, 19, 397-408.	1.4	15
203	Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 301-309.	1.2	30
204	In vivo binding of a tau imaging probe, [11C]PBB3, in patients with progressive supranuclear palsy. Movement Disorders, 2019, 34, 744-754.	2.2	36
205	The language profile of progressive supranuclear palsy. Cortex, 2019, 115, 294-308.	1.1	31
206	Imaging counterpart of postural instability and vertical ocular dysfunction in patients with PSP: A multimodal MRI study. Parkinsonism and Related Disorders, 2019, 63, 124-130.	1.1	25

#	Article	IF	Citations
207	Î±â€Synuclein realâ€time quakingâ€induced conversion in the cerebrospinal fluid of uncertain cases of parkinsonism. Annals of Neurology, 2019, 85, 777-781.	2.8	94
208	Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy. Movement Disorders, 2019, 34, 1144-1153.	2.2	98
209	Cognitive deficits in progressive supranuclear palsy on the Repeatable Battery for the Assessment of Neuropsychological Status. Journal of Clinical and Experimental Neuropsychology, 2019, 41, 469-475.	0.8	12
210	Striatal dopamine activity and myocardial 123I-metaiodobenzylguanidine uptake in early Parkinson's disease. Parkinsonism and Related Disorders, 2019, 63, 156-161.	1.1	9
211	When hoofbeats are zebras: Late onset niemann-pick disease type C overlapping with frontotemporal dementia. European Neuropsychopharmacology, 2019, 29, S452-S453.	0.3	0
212	Salivary alpha-synuclein in the diagnosis of Parkinson's disease and Progressive Supranuclear Palsy. Parkinsonism and Related Disorders, 2019, 63, 143-148.	1.1	61
213	Movement Disorders with Dementia in Older Adults. Clinical Handbooks in Neuropsychology, 2019, , 543-575.	0.1	0
214	A Home-Based, Music-Cued Movement Program Is Feasible and May Improve Gait in Progressive Supranuclear Palsy. Frontiers in Neurology, 2019, 10, 116.	1.1	20
215	Cerebrospinal Fluid and Plasma Biomarkers in Neurodegenerative Diseases. Journal of Alzheimer's Disease, 2019, 68, 395-404.	1.2	33
216	Neuroradiological and clinical features in ophthalmoplegia. Neuroradiology, 2019, 61, 365-387.	1.1	5
217	Refining initial diagnosis of Parkinson's disease after followâ€up: A 4â€year prospective clinical and magnetic resonance imaging study. Movement Disorders, 2019, 34, 487-495.	2.2	22
218	Diagnostic positif et Ã©tiologique des dÃ©mences frontotemporales. Pratique Neurologique - FMC, 2019, 10, 101-111.	0.1	0
219	Demencias degenerativas: Â¿un dilema de sÃndromes o de enfermedades?. NeurologÃa, 2019, , .	0.3	0
220	The clinico-metabolic correlates of language impairment in corticobasal syndrome and progressive supranuclear palsy. NeuroImage: Clinical, 2019, 24, 102009.	1.4	15
221	â€œFeasibility and utility of a simple computerized test for measuring saccade latency in progressive supranuclear palsy- a proof-of-concept studyâ€• Journal of Clinical Movement Disorders, 2019, 6, 6.	2.2	0
222	Recognizing and treating atypical Parkinson disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 301-320.	1.0	10
223	How to approach a patient with parkinsonism â€“ red flags for atypical parkinsonism. International Review of Neurobiology, 2019, 149, 1-34.	0.9	4
224	Classification of atypical parkinsonism per pathology versus phenotype. International Review of Neurobiology, 2019, 149, 37-47.	0.9	10

#	Article	IF	Citations
225	Exercise and Progressive Supranuclear Palsy: the need for explicit exercise reporting. BMC Neurology, 2019, 19, 305.	0.8	8
226	Multilingual Validation of the First French Version of Munich Dysphagia Testâ€"Parkinson's Disease (MDT-PD) in the Luxembourg Parkinson's Study. Frontiers in Neurology, 2019, 10, 1180.	1.1	3
227	APPâ€derived peptides reflect neurodegeneration in frontotemporal dementia. Annals of Clinical and Translational Neurology, 2019, 6, 2518-2530.	1.7	13
228	Genetic mimics of the non-genetic atypical parkinsonian disorders â€“ the â€˜atypicalâ€™ atypical. International Review of Neurobiology, 2019, 149, 327-351.	0.9	8
229	Parkinsonism in frontotemporal dementias. International Review of Neurobiology, 2019, 149, 249-275.	0.9	24
230	Progressive supranuclear palsy. International Review of Neurobiology, 2019, 149, 49-86.	0.9	19
231	Parkinsonism in neurodegenerative diseases predominantly presenting with ataxia. International Review of Neurobiology, 2019, 149, 277-298.	0.9	7
232	Is ¹²³I-MIBG Scintigraphy Beneficial or Excessive for the Diagnosis of Parkinsonâ€™s Disease in the Early Phase?. Neurodegenerative Diseases, 2019, 19, 88-95.	0.8	4
233	Alexithymia and anhedonia in early Richardson's syndrome and progressive supranuclear palsy with predominant parkinsonism. Brain and Behavior, 2019, 9, e01448.	1.0	9
234	Ocular motor manifestations of movement disorders. Current Opinion in Ophthalmology, 2019, 30, 443-448.	1.3	5
235	Thalamic and cerebellar hypoperfusion in single photon emission computed tomography may differentiate multiple system atrophy and progressive supranuclear palsy. Medicine (United States), 2019, 98, e16603.	0.4	6
236	Neurological profiles beyond the sleep disorder in patients with anti-IgLON5 disease. Current Opinion in Neurology, 2019, 32, 493-499.	1.8	43
237	Frequency of the TREM2 R47H Variant in Various Neurodegenerative Disorders. Alzheimer Disease and Associated Disorders, 2019, 33, 327-330.	0.6	6
238	Adverse motor effects of progressive supranuclear palsy with frontal lobe signs: A case report. Geriatrics and Gerontology International, 2019, 19, 1184-1186.	0.7	2
239	Initial Versus Follow-up Sequential Myocardial 123I-MIBG Scintigraphy to Discriminate Parkinson Disease From Atypical Parkinsonian Syndromes. Clinical Nuclear Medicine, 2019, 44, 282-288.	0.7	22
240	Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. Parkinsonism and Related Disorders, 2019, 60, 138-145.	1.1	7
241	What a neurologist should know about PET and SPECT functional imaging for parkinsonism: A practical perspective. Parkinsonism and Related Disorders, 2019, 59, 93-100.	1.1	29
242	Review: Clinical, genetic and neuroimaging features of frontotemporal dementia. Neuropathology and Applied Neurobiology, 2019, 45, 6-18.	1.8	32

#	Article	IF	Citations
243	In vivo evidence for decreased scyllo-inositol levels in the supplementary motor area of patients with Progressive Supranuclear Palsy: A proton MR spectroscopy study. Parkinsonism and Related Disorders, 2019, 62, 185-191.	1.1	19
244	Unusual gait disorders: a phenomenological approach and classification. Expert Review of Neurotherapeutics, 2019, 19, 119-132.	1.4	6
245	Network Imaging in Parkinsonian and Other Movement Disorders: Network Dysfunction and Clinical Correlates. International Review of Neurobiology, 2019, 144, 143-184.	0.9	6
246	The Neural Correlates of Impaired Self-Monitoring Among Individuals With Neurodegenerative Dementias. Journal of Neuropsychiatry and Clinical Neurosciences, 2019, 31, 201-209.	0.9	11
247	Quantifying apraxia and ophthalmokinetic abnormalities in patients with atypical Parkinsonism: A new way to differential diagnosis?. Parkinsonism and Related Disorders, 2019, 61, 39-44.	1.1	2
248	Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls. Molecular Neurobiology, 2019, 56, 5067-5074.	1.9	7
249	MRI Outperforms [18F]AVâ€1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. Movement Disorders, 2019, 34, 105-113.	2.2	33
250	Progressive Supranuclear Palsy-like Syndrome from Possible Cerebral Amyloid Angiopathy. Canadian Journal of Neurological Sciences, 2019, 46, 132-136.	0.3	2
251	Reply to the comments on â€œUnusual case of idiopathic normal pressure hydrocephalus initially presenting as Parinaudâ€™s syndrome?â€• Geriatrics and Gerontology International, 2019, 19, 84-85.	0.7	0
252	Tau PET imaging in neurodegenerative tauopathiesâ€”still a challenge. Molecular Psychiatry, 2019, 24, 1112-1134.	4.1	409
253	Swedish Version of the Hayling Test: Clinical Utility in Frontotemporal Dementia Syndromes. Journal of the International Neuropsychological Society, 2019, 25, 195-203.	1.2	3
254	Therapeutic trial design for frontotemporal dementia and related disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 412-423.	0.9	21
255	Medical decision-making in progressive supranuclear palsy: A comparison to other neurodegenerative disorders. Parkinsonism and Related Disorders, 2019, 61, 77-81.	1.1	7
256	Electroencephalography in primary progressive aphasia and apraxia of speech. Aphasiology, 2019, 33, 1410-1417.	1.4	9
257	Track density imaging in progressive supranuclear palsy: A pilot study. Human Brain Mapping, 2019, 40, 1729-1737.	1.9	8
258	Parkinsonâ€™s Disease. Medical Clinics of North America, 2019, 103, 337-350.	1.1	269
259	Red flags phenotyping: A systematic review on clinical features in atypical parkinsonian disorders. Parkinsonism and Related Disorders, 2019, 59, 82-92.	1.1	22
260	Cognitive decline on the Repeatable Battery for the Assessment of Neuropsychological Status in progressive supranuclear palsy. Clinical Neuropsychologist, 2020, 34, 529-540.	1.5	5

#	Article	IF	Citations
261	Exercise and physical activity for people with Progressive Supranuclear Palsy: a systematic review. Clinical Rehabilitation, 2020, 34, 23-33.	1.0	15
262	Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 342-354.	3.3	61
263	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4â€Repeat Tauopathies. Movement Disorders, 2020, 35, 171-176.	2.2	37
264	18F-AV1451 PET imaging and multimodal MRI changes in progressive supranuclear palsy. Journal of Neurology, 2020, 267, 341-349.	1.8	21
265	Incidence and Trends of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Population-Based Study. Journal of Parkinson's Disease, 2020, 10, 179-184.	1.5	15
266	Cerebrospinal fluid levels of alpha-synuclein, amyloid Î², tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinsonâ€™s disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings. Neuroscience Letters, 2020, 715, 134564.	1.0	8
267	Chameleons and mimics: Progressive supranuclear palsy and corticobasal degeneration. Neuropathology, 2020, 40, 57-67.	0.7	16
268	Dysphagia in Progressive Supranuclear Palsy. Dysphagia, 2020, 35, 667-676.	1.0	25
269	New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures. Alzheimer's and Dementia, 2020, 16, 131-143.	0.4	45
270	Midbrain MRI assessments in progressive supranuclear palsy subtypes. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 98-103.	0.9	39
271	Very Lateâ€Onset Niemann Pick Type C Disease: Example of Progressive Supranuclear Palsy Lookâ€Alike Disorder. Movement Disorders Clinical Practice, 2020, 7, 211-214.	0.8	7
272	Serum adiponectin levels between patients with Parkinsonâ€™s disease and those with PSP. Neurological Sciences, 2020, 41, 1125-1131.	0.9	5
273	Differences in cerebellar perfusion between Parkinson's disease and multiple system atrophy. Journal of the Neurological Sciences, 2020, 409, 116627.	0.3	6
274	CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia. Alzheimer's Research and Therapy, 2020, 12, 2.	3.0	86
275	Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. JAMA Neurology, 2020, 77, 377.	4.5	94
276	Diagnosis and Differential Diagnosis of Parkinson Disease. Clinics in Geriatric Medicine, 2020, 36, 13-24.	1.0	15
277	Multimodal Magnetic Resonance Imaging Quantification of Brain Changes in Progressive Supranuclear Palsy. Movement Disorders, 2020, 35, 161-170.	2.2	31
278	Progressive supranuclear palsy and pawpaw. Neurology: Clinical Practice, 2020, 10, e17-e18.	0.8	1

#	Article	IF	Citations
279	Graphic Summary of Movement Disorders Society Criteria for Progressive Supranuclear Palsy and Multiple Allocations eXtinction Rules. Movement Disorders Clinical Practice, 2020, 7, 240-242.	0.8	1
280	Combination of midbrain-to-pontine ratio and cardiac MIBG scintigraphy to differentiate Parkinson's disease from multiple system atrophy and progressive supranuclear palsy. Clinical Parkinsonism & Related Disorders, 2020, 2, 20-24.	0.5	1
281	Evolving concepts on bradykinesia. Brain, 2020, 143, 727-750.	3.7	120
282	Falls in Progressive Supranuclear Palsy. Movement Disorders Clinical Practice, 2020, 7, 16-24.	0.8	16
283	Disentangling brain functional network remodeling in corticobasal syndrome â€“ A multimodal MRI study. NeuroImage: Clinical, 2020, 25, 102112.	1.4	10
284	The Progressive Supranuclear Palsy: Past and Present Aspects. Clinical Gerontologist, 2020, 43, 155-180.	1.2	8
285	Midbrain morphology in idiopathic normal pressure hydrocephalus: A progressive supranuclear palsy mimic. Acta Neurologica Scandinavica, 2020, 141, 328-334.	1.0	18
286	Lentiform Nucleus Hyperechogenicity in Parkinsonian Syndromes: A Systematic Review and Meta-Analysis with Consideration of Molecular Pathology. Cells, 2020, 9, 2.	1.8	15
287	Prediction of the Clinical Severity of Progressive Supranuclear Palsy by Diffusion Tensor Imaging. Journal of Clinical Medicine, 2020, 9, 40.	1.0	6
288	The neutrophil-to-lymphocyte ratio as a marker of peripheral inflammation in progressive supranuclear palsy: a retrospective study. Neurological Sciences, 2020, 41, 1233-1237.	0.9	14
289	The evolution of parkinsonism in primary progressive apraxia of speech: A 6-year longitudinal study. Parkinsonism and Related Disorders, 2020, 81, 34-40.	1.1	20
290	Comparison of Amyloid in Cerebrospinal Fluid, Brain Imaging, and Autopsy in a Case of Progressive Supranuclear Palsy. Alzheimer Disease and Associated Disorders, 2020, 34, 275-277.	0.6	2
291	Cell-free amplification of prions: Where do we stand?. Progress in Molecular Biology and Translational Science, 2020, 175, 325-358.	0.9	7
292	The â€œgunslingerâ€•sign in progressive supranuclear palsy â€“ Richardson variant. Journal of the Neurological Sciences, 2020, 418, 117108.	0.3	2
293	Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy. Parkinsonism and Related Disorders, 2020, 78, 200-203.	1.1	8
294	The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. Parkinsonism and Related Disorders, 2020, 79, 121-126.	1.1	11
295	The movement disorder society clinical criteria for progressive supranuclear palsy:The movie version. Parkinsonism and Related Disorders, 2020, 78, 198-199.	1.1	2
296	Diagnostic Performance of ¹²³I-FPCIT SPECT Specific Binding Ratio in Progressive Supranuclear Palsy: Use of Core Clinical Features and MRI for Comparison. American Journal of Roentgenology, 2020, 215, 1443-1448.	1.0	5

#	Article	IF	Citations
297	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurology, The, 2020, 19, 951-962.	4.9	254
298	Multimodal analysis of gene expression from postmortem brains and blood identifies synaptic vesicle trafficking genes to be associated with Parkinsonâ€™s disease. Briefings in Bioinformatics, 2021, 22, .	3.2	20
299	Relationship between tongue pressure and functional oral intake scale diet type in patients with neurological and neuromuscular disorders. Clinical Neurology and Neurosurgery, 2020, 198, 106196.	0.6	7
300	Differential patterns of internally generated responses in parkinsonian disorders. Neuropsychologia, 2020, 146, 107569.	0.7	5
301	Mean Apparent Propagator MRI Is Better Than Conventional Diffusion Tensor Imaging for the Evaluation of Parkinsonâ€™s Disease: A Prospective Pilot Study. Frontiers in Aging Neuroscience, 2020, 12, 563595.	1.7	26
302	The â€œzig-zagâ€•sign in Progressive Supranuclear Palsy. Parkinsonism and Related Disorders, 2020, 79, 86-87.	1.1	3
304	Lower Energy Intake among Advanced vs. Early Parkinsonâ€™s Disease Patients and Healthy Controls in a Clinical Lunch Setting: A Cross-Sectional Study. Nutrients, 2020, 12, 2109.	1.7	8
305	Synaptic Loss in Primary Tauopathies Revealed by [<scp>¹¹C</scp>]<scp>UCBâ€‰</scp> Positron Emission Tomography. Movement Disorders, 2020, 35, 1834-1842.	2.2	61
306	ATN status in amnestic and non-amnestic Alzheimerâ€™s disease and frontotemporal lobar degeneration. Brain, 2020, 143, 2295-2311.	3.7	24
307	Clinical, MRI and 18F-FDG-PET/CT analysis of progressive supranuclear palsy. Journal of Clinical Neuroscience, 2020, 80, 318-323.	0.8	7
308	Four-Repeat Tauopathies: Current Management and Future Treatments. Neurotherapeutics, 2020, 17, 1563-1581.	2.1	24
309	Extrastriatal 123I-FP-CIT SPECT impairment in degenerative parkinsonisms. Parkinsonism and Related Disorders, 2020, 78, 38-43.	1.1	10
310	PSP-FTD Complex: A Possible Variant of PSP. American Journal of Alzheimer's Disease and Other Dementias, 2020, 35, 153331752092238.	0.9	1
311	Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies. International Journal of Molecular Sciences, 2020, 21, 8948.	1.8	53
312	Gait improvement after levofloxacin administration in a progressive supranuclear palsy patient. Clinical Parkinsonism & Related Disorders, 2020, 3, 100080.	0.5	1
313	Neuropsychological assessment could distinguish among different clinical phenotypes of progressive supranuclear palsy: A Machine Learning approach. Journal of Neuropsychology, 2021, 15, 301-318.	0.6	11
314	Longitudinal Amyloid-Î² PET in Atypical Alzheimerâ€™s Disease and Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2020, 74, 377-389.	1.2	7
315	Association of MRI Measures With Disease Severity and Progression in Progressive Supranuclear Palsy. Frontiers in Neurology, 2020, 11, 603161.	1.1	8

#	Article	IF	Citations
316	MDS criteria for the diagnosis of progressive supranuclear palsy overemphasize Richardson syndrome. Annals of Clinical and Translational Neurology, 2020, 7, 1702-1707.	1.7	7
317	Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases. Molecular Neurobiology, 2020, 57, 4667-4691.	1.9	33
318	Suicidal and death ideation in patients with progressive supranuclear palsy and corticobasal syndrome. Journal of Affective Disorders, 2020, 276, 1061-1068.	2.0	8
319	Aberrant interaction between FUS and SFPQ in neurons in a wide range of FTLDÂspectrum diseases. Brain, 2020, 143, 2398-2405.	3.7	23
320	Cerebrospinal Fluid Biomarkers in Parkinsonâ€™s Disease: A Critical Overview of the Literature and Meta-Analyses. Brain Sciences, 2020, 10, 466.	1.1	26
321	The Role of Magnetic Resonance Imaging for the Diagnosis of Atypical Parkinsonism. Frontiers in Neurology, 2020, 11, 665.	1.1	22
322	Magnetic resonance parkinsonism indices and interpeduncular angle in idiopathic normal pressure hydrocephalus and progressive supranuclear palsy. Neuroradiology, 2020, 62, 1657-1665.	1.1	11
323	Towards accurate and unbiased imaging-based differentiation of Parkinsonâ€™s disease, progressive supranuclear palsy and corticobasal syndrome. Brain Communications, 2020, 2, fcaa051.	1.5	14
324	Immunotherapy in progressive supranuclear palsy. Current Opinion in Neurology, 2020, 33, 527-533.	1.8	8
325	Comparative analysis of non-motor symptoms in patients with Parkinsonâ€™s Disease and atypical parkinsonisms. Clinical Neurology and Neurosurgery, 2020, 197, 106088.	0.6	9
326	Compensating for choroid plexus based off-target signal in the hippocampus using 18F-flortaucipir PET. NeuroImage, 2020, 221, 117193.	2.1	9
327	GABA and glutamate deficits from frontotemporal lobar degeneration are associated with disinhibition. Brain, 2020, 143, 3449-3462.	3.7	55
328	Amyloid and Tau PET Imaging of Alzheimer Disease and Other Neurodegenerative Conditions. Seminars in Ultrasound, CT and MRI, 2020, 41, 572-583.	0.7	12
329	Lâ€™anarthrie primaire progressiveÂ: nouveaux critÃ¨res diagnostiques. NPG Neurologie - Psychiatrie - Geriatrie, 2020, 20, 147-151.	0.1	0
330	Contribution of the astrocytic tau pathology to synapse loss in progressive supranuclear palsy and corticobasal degeneration. Brain Pathology, 2021, 31, e12914.	2.1	16
331	Two Patients with Niemann Pick Disease Type C Diagnosed in the Seventh Decade of Life. Movement Disorders Clinical Practice, 2020, 7, 961-964.	0.8	3
332	Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy. Annals of Neurology, 2020, 88, 1194-1204.	2.8	38
333	Microglial Activation and Inflammation as a Factor in the Pathogenesis of Progressive Supranuclear Palsy (PSP). Frontiers in Neuroscience, 2020, 14, 893.	1.4	33

#	Article	IF	Citations
334	Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinsonâ€™s disease. Npj Parkinson's Disease, 2020, 6, 21.	2.5	17
335	Astrocytic 3-Repeat Tau Pathologies in Progressive Supranuclear Palsy. Journal of Neuropathology and Experimental Neurology, 2020, 79, 1015-1018.	0.9	1
336	Automated brainstem volumetry can aid in the diagnostics of parkinsonian disorders. Parkinsonism and Related Disorders, 2020, 79, 18-25.	1.1	12
337	Clinical Conditions â€œSuggestive of Progressive Supranuclear Palsyâ€â€”Diagnostic Performance. Movement Disorders, 2020, 35, 2301-2313.	2.2	22
338	Assessment of ¹⁸F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurology, 2020, 77, 1408.	4.5	145
339	Associations of mitochondrial genomic variation with corticobasal degeneration, progressive supranuclear palsy, and neuropathological tau measures. Acta Neuropathologica Communications, 2020, 8, 162.	2.4	9
340	Immune profiling of plasma-derived extracellular vesicles identifies Parkinson disease. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	45
341	Degeneration of the locus coeruleus is a common feature of tauopathies and distinct from TDP-43 proteinopathies in the frontotemporal lobar degeneration spectrum. Acta Neuropathologica, 2020, 140, 675-693.	3.9	15
342	Ontario Neurodegenerative Disease Research Initiative (ONDRI): Structural MRI Methods and Outcome Measures. Frontiers in Neurology, 2020, 11, 847.	1.1	23
343	Hospitalization Rates and Comorbidities in Patients with Progressive Supranuclear Palsy in Germany from 2010 to 2017. Journal of Clinical Medicine, 2020, 9, 2454.	1.0	3
344	Multicenter Validation of Metabolic Abnormalities Related to <scp>PSP</scp> According to the <scp>MDSâ€PSP</scp> Criteria. Movement Disorders, 2020, 35, 2009-2018.	2.2	18
345	Iron Serum Markers Profile in Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2020, 78, 1373-1380.	1.2	3
346	Clinical and Electrophysiological Hints to TMS in De Novo Patients with Parkinsonâ€™s Disease and Progressive Supranuclear Palsy. Journal of Personalized Medicine, 2020, 10, 274.	1.1	24
347	Differential diagnosis of parkinsonism: a head-to-head comparison of FDG PET and MIBG scintigraphy. Npj Parkinson's Disease, 2020, 6, 39.	2.5	8
348	Gait initiation in progressive supranuclear palsy: brain metabolic correlates. NeuroImage: Clinical, 2020, 28, 102408.	1.4	21
349	18F-THK5351 PET imaging in patients with progressive supranuclear palsy: associations with core domains and diagnostic certainty. Scientific Reports, 2020, 10, 19410.	1.6	10
350	18F-flortaucipir PET to autopsy comparisons in Alzheimerâ€™s disease and other neurodegenerative diseases. Brain, 2020, 143, 3477-3494.	3.7	100
351	Prevalence of heterozygous mutations in Niemann-Pick type C genes in a cohort of progressive supranuclear palsy. Parkinsonism and Related Disorders, 2020, 79, 9-10.	1.1	4

#	Article	IF	Citations
352	Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes. Frontiers in Neurology, 2020, 11, 572976.	1.1	65
353	What is causing this patient's balance and speech problems?. JAAPA: Official Journal of the American Academy of Physician Assistants, 2020, 33, 55-57.	0.1	0
354	Tauopathy and Movement Disordersâ€"Unveiling the Chameleons and Mimics. Frontiers in Neurology, 2020, 11, 599384.	1.1	16
355	A new tetra-plex fluorimetric assay for the quantification of cerebrospinal fluid Î²-amyloid42, total-tau, phospho-tau and Î±-synuclein in the differential diagnosis of neurodegenerative dementia. Journal of Neurology, 2020, 267, 2567-2581.	1.8	6
356	Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathologica, 2020, 140, 99-119.	3.9	210
357	EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1885-1912.	3.3	134
358	Ioflupane 123I (DAT scan) SPECT identifies dopamine receptor dysfunction early in the disease course in progressive apraxia of speech. Journal of Neurology, 2020, 267, 2603-2611.	1.8	12
359	Magnetic Resonance Imaging Biomarkers Distinguish Normal Pressure Hydrocephalus From Progressive Supranuclear Palsy. Movement Disorders, 2020, 35, 1406-1415.	2.2	31
360	Clinical and Molecular Characterization of a Novel Progranulin Deletion Associated with Different Phenotypes. Journal of Alzheimer's Disease, 2020, 76, 341-347.	1.2	5
361	Is brain perfusion a differentiating feature in the comparison of Progressive Supranuclear Palsy Syndrome (PSPS) and Corticobasal Syndrome (CBS)?. Journal of Clinical Neuroscience, 2020, 77, 123-127.	0.8	5
362	Asymmetry index of Blink Reflex Recovery Cycle differentiates Parkinsonâ€™s disease from atypical Parkinsonian syndromes. Journal of Neurology, 2020, 267, 1859-1863.	1.8	6
363	Parkinson's disease or atypical parkinsonism? The importance of acoustic voice analysis in differential diagnosis of speech disorders. Brain and Behavior, 2020, 10, e01700.	1.0	17
364	Optimizing Treatment in Undertreated Late-Stage Parkinsonism: A Pragmatic Randomized Trial. Journal of Parkinson's Disease, 2020, 10, 1171-1184.	1.5	6
365	Appropriate assessment method of 123I-MIBG myocardial scintigraphy for the diagnosis of Lewy body diseases and idiopathic REM sleep behavior disorder. Journal of Neurology, 2020, 267, 3248-3257.	1.8	5
366	The Added Value of Tau-PET in the Assessment of Progressive Supranuclear Palsy. Clinical Nuclear Medicine, 2020, 45, e239-e240.	0.7	1
367	Patient and care partner views on exercise and structured physical activity for people with Progressive Supranuclear Palsy. PLoS ONE, 2020, 15, e0234265.	1.1	6
368	Increased Noradrenaline as an Additional Cerebrospinal Fluid Biomarker in PSP-Like Parkinsonism. Frontiers in Aging Neuroscience, 2020, 12, 126.	1.7	5
369	A Convenient Prognostic Tool and Staging System for Progressive Supranuclear Palsy. Movement Disorders Clinical Practice, 2020, 7, 664-671.	0.8	8

#	Article	IF	Citations
370	Progressive Supranuclear Palsyâ€"Parkinsonism Predominant (PSP-P)â€"A Clinical Challenge at the Boundaries of PSP and Parkinson's Disease (PD). Frontiers in Neurology, 2020, 11, 180.	1.1	61
371	Dysarthria enhancement mechanism under external clear speech instruction in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. Journal of Neural Transmission, 2020, 127, 905-914.	1.4	7
372	Molecular profiling in Parkinsonian syndromes: CSF biomarkers. Clinica Chimica Acta, 2020, 506, 55-66.	0.5	2
374	Development of disease-modifying drugs for frontotemporal dementia spectrum disorders. Nature Reviews Neurology, 2020, 16, 213-228.	4.9	73
375	Non-Invasive Cerebellar Stimulation in Neurodegenerative Ataxia: A Literature Review. International Journal of Molecular Sciences, 2020, 21, 1948.	1.8	39
376	Association of Tripartite Motif Containing 11 rs564309 With Tau Pathology in Progressive Supranuclear Palsy. Movement Disorders, 2020, 35, 890-894.	2.2	6
377	Copathology in Progressive Supranuclear Palsy: Does It Matter?. Movement Disorders, 2020, 35, 984-993.	2.2	48
378	Insight in frontotemporal dementia and progressive supranuclear palsy. Neurological Sciences, 2020, 41, 2135-2142.	0.9	3
379	Parkinsonian Syndrome with Frontal Lobe Involvement and Anti-Glycine Receptor Antibodies. Brain Sciences, 2020, 10, 399.	1.1	7
380	Diagnostic and prognostic value of serum NfL and p-Tau₁₈₁in frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 960-967.	0.9	93
381	Design and Operation of the Lombardy Parkinson's Disease Network. Frontiers in Neurology, 2020, 11, 573.	1.1	3
382	Methods and utility of quantitative brainstem measurements in progressive supranuclear palsy versus Parkinson's disease in a routine clinical setting. Clinical Parkinsonism & Related Disorders, 2020, 3, 100033.	0.5	0
383	Reproducibility and reaction time of swallowing as markers of dysphagia in parkinsonian syndromes. Clinical Neurophysiology, 2020, 131, 2200-2208.	0.7	4
384	PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers. Frontiers in Neurology, 2020, 11, 574.	1.1	7
385	Apraxia of Eyelid Opening Improved by Pallidal Stimulation in Progressive Supranuclear Palsy. Movement Disorders Clinical Practice, 2020, 7, 698-700.	0.8	2
386	Magnetic Resonance Parkinsonism Index for evaluating disease progression rate in progressive supranuclear palsy: A longitudinal 2-year study. Parkinsonism and Related Disorders, 2020, 72, 1-6.	1.1	26
387	My dad and progressive supranuclear palsy (PSP). Practical Neurology, 2020, 20, 263-264.	0.5	0
388	Interrelation between Sarcopenia and the Number of Motor Neurons in Patients with Parkinsonian Syndromes. Gerontology, 2020, 66, 409-415.	1.4	19

#	Article	IF	Citations
389	Progressive supranuclear palsy and primary lateral sclerosis secondary to globular glial tauopathy: a case report and a practical theoretical framework for the clinical prediction of this rare pathological entity. Neurocase, 2020, 26, 91-97.	0.2	12
390	Plasma P-tau181 in Alzheimerâ€™s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimerâ€™s dementia. Nature Medicine, 2020, 26, 379-386.	15.2	643
391	Diagnostic value of plasma phosphorylated tau181 in Alzheimerâ€™s disease and frontotemporal lobar degeneration. Nature Medicine, 2020, 26, 387-397.	15.2	471
392	Novel ELISAs to measure total and phosphorylated tau in cerebrospinal fluid. Neuroscience Letters, 2020, 722, 134826.	1.0	4
393	The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. Expert Review of Molecular Diagnostics, 2020, 20, 421-441.	1.5	42
394	Discriminating progressive supranuclear palsy from Parkinson's disease using wearable technology and machine learning. Gait and Posture, 2020, 77, 257-263.	0.6	49
395	Progressive supranuclear palsy presenting with hyperkinetic movement disorder and hemiplegic dystonia: a case report. International Journal of Neuroscience, 2020, 130, 1278-1281.	0.8	1
396	Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study. Movement Disorders, 2020, 35, 976-983.	2.2	38
397	Neural circuits of idiopathic Normal Pressure Hydrocephalus: A perspective review of brain connectivity and symptoms meta-analysis. Neuroscience and Biobehavioral Reviews, 2020, 112, 452-471.	2.9	12
398	Diagnostic potential of automated tractography in progressive supranuclear palsy variants. Parkinsonism and Related Disorders, 2020, 72, 65-71.	1.1	11
399	Clinical Reasoning: A 58-year-old woman presents with progressive memory deficits, odd behavior, and falls. Neurology, 2020, 94, e557-e561.	1.5	0
400	Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. NeuroImage: Clinical, 2020, 25, 102152.	1.4	46
401	Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases. Alzheimer's Research and Therapy, 2020, 12, 19.	3.0	29
402	Nonmercaptalbumin as an oxidative stress marker in Parkinsonâ€™s and PARK2 disease. Annals of Clinical and Translational Neurology, 2020, 7, 307-317.	1.7	22
403	The Role of Free and Cued Selective Reminding Test in Predicting [18F]Florbetaben PET Results in Mild Cognitive Impairment and Mild Dementia. Journal of Alzheimer's Disease, 2020, 73, 1647-1659.	1.2	4
404	Pathologyâ€Proven Corticobasal Degeneration Presenting as Richardson's Syndrome. Movement Disorders Clinical Practice, 2020, 7, 267-272.	0.8	6
405	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 263-270.	0.9	106
406	The Progressive Supranuclear Palsy Clinical Deficits Scale. Movement Disorders, 2020, 35, 650-661.	2.2	31

#	Article	IF	Citations
407	Inflammation biomarker discovery in Parkinsonâ€™s disease and atypical parkinsonisms. BMC Neurology, 2020, 20, 26.	0.8	51
408	Alien limb in the corticobasal syndrome: phenomenological characteristics and relationship to apraxia. Journal of Neurology, 2020, 267, 1147-1157.	1.8	11
409	Prediagnostic motor and non-motor symptoms in progressive supranuclear palsy: The step-back PSP study. Parkinsonism and Related Disorders, 2020, 74, 67-73.	1.1	23
410	Imaging biomarkers in neurodegeneration: current and future practices. Alzheimer's Research and Therapy, 2020, 12, 49.	3.0	96
411	Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	58
412	CSF Ubiquitin Levels Are Higher in Alzheimerâ€™s Disease than in Frontotemporal Dementia and Reflect the Molecular Subtype in Prion Disease. Biomolecules, 2020, 10, 497.	1.8	8
413	Magnetic Resonance Imaging and Neurofilament Light in the Differentiation of Parkinsonism. Movement Disorders, 2020, 35, 1388-1395.	2.2	15
414	Shared Metabolic Profile of Caffeine in Parkinsonian Disorders. Movement Disorders, 2020, 35, 1438-1447.	2.2	8
415	Progressive Supranuclear Palsy and Statin Use. Movement Disorders, 2020, 35, 1253-1257.	2.2	2
416	Role of [18F]-FDG PET in patients with atypical parkinsonism associated with dementia. Clinical and Translational Imaging, 2020, 8, 107-122.	1.1	3
417	Gradient subthalamic neurodegeneration and tau pathology in the hypoglossal nucleus as essential pathological markers of progressive supranuclear palsyÂâ€“ÂRichardson syndrome. Revue Neurologique, 2020, 176, 353-360.	0.6	1
418	Differential diagnosis of parkinsonian syndromes: a comparison of clinical and automated - metabolic brain patternsâ€™ based approach. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2901-2910.	3.3	23
419	Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathologica, 2020, 140, 49-62.	3.9	218
420	Metabolomic changes associated with frontotemporal lobar degeneration syndromes. Journal of Neurology, 2020, 267, 2228-2238.	1.8	12
421	Genetic forms of frontotemporal lobar degeneration: Current diagnostic approach and new directions in therapeutic strategies. Revue Neurologique, 2020, 176, 571-581.	0.6	9
422	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nature Reviews Neurology, 2020, 16, 265-284.	4.9	121
423	Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2911-2922.	3.3	36
424	Looking into the prediagnostic phase of progressive supranuclear palsy. Parkinsonism and Related Disorders, 2020, 74, 74-75.	1.1	1

#	Article	IF	Citations
425	<scp>Openâ€Label</scp> Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy. Movement Disorders Clinical Practice, 2020, 7, 440-447.	0.8	34
426	DCTN1 mutation analysis in Italian patients with PSP, MSA, and DLB. Neurobiology of Aging, 2020, 93, 143.e5-143.e7.	1.5	3
427	Midbrain/pons area ratio and clinical features predict the prognosis of progressive Supranuclear palsy. BMC Neurology, 2020, 20, 114.	0.8	10
428	Swallow tail sign on susceptibility map-weighted imaging (SMWI) for disease diagnosing and severity evaluating in parkinsonism. Acta Radiologica, 2021, 62, 234-242.	0.5	9
429	A Clinicopathologic Study of Movement Disorders in Frontotemporal Lobar Degeneration. Movement Disorders, 2021, 36, 632-641.	2.2	3
430	A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study. Movement Disorders, 2021, 36, 681-689.	2.2	22
431	Clinical impact of 18F-FDG-PET among memory clinic patients with uncertain diagnosis. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 612-622.	3.3	16
432	The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases. American Journal of Geriatric Psychiatry, 2021, 29, 375-383.	0.6	36
433	Primary progressive apraxia of speech: from recognition to diagnosis and care. Aphasiology, 2021, 35, 560-591.	1.4	45
434	The Role of Vocal Fold Bowing on Cough and Swallowing Dysfunction in Progressive Supranuclear Palsy. Laryngoscope, 2021, 131, 1217-1222.	1.1	10
435	Eye movements and association with regional brain atrophy in clinical subtypes of progressive supranuclear palsy. Journal of Neurology, 2021, 268, 967-977.	1.8	7
436	Cricopharyngeal bar on videofluoroscopy: high specificity for inclusion body myositis. Journal of Neurology, 2021, 268, 1016-1024.	1.8	9
437	In Vivo Assessment of Neuroinflammation in <scp>4â€Repeat</scp> Tauopathies. Movement Disorders, 2021, 36, 883-894.	2.2	37
438	Is Levodopa Response a Valid Indicator of Parkinson's Disease?. Movement Disorders, 2021, 36, 948-954.	2.2	26
439	Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism. Parkinsonism and Related Disorders, 2021, 82, 87-91.	1.1	16
440	Asymmetric, multifocal musculoskeletal pain preceding the onset of progressive supranuclear palsy: A case report. CNS Neuroscience and Therapeutics, 2021, 27, 256-258.	1.9	1
441	Altered ioflupane singleâ€photon emission computed tomography in antiâ€IgLON5 disease: A new case mimicking probable progressive supranuclear palsy and review of the literature. European Journal of Neurology, 2021, 28, 1392-1395.	1.7	18
442	Abnormal structural connectivity in progressive supranuclear palsyâ€"Richardson syndrome. Acta Neurologica Scandinavica, 2021, 143, 430-440.	1.0	1

#	Article	IF	Citations
443	<scp>FDGâ€PET</scp> Patterns Predict Amyloid Deposition and Clinical Profile in Corticobasal Syndrome. Movement Disorders, 2021, 36, 651-661.	2.2	22
444	Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Neuron, 2021, 109, 448-460.e4.	3.8	56
445	Immunohistochemical Detection of Synuclein Pathology in Skin in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinsonism. Movement Disorders, 2021, 36, 895-904.	2.2	31
446	Progressive supranuclear palsy: Neuropathology of patients with a short disease duration due to unexpected death. Neuropathology, 2021, 41, 174-182.	0.7	5
447	Atypical parkinsonian syndromes in a North African tertiary referral center. Brain and Behavior, 2021, 11, e01924.	1.0	5
448	Investigating the 1-year decline in midbrain-to-pons ratio in the differential diagnosis of PSP and IPD. Journal of Neurology, 2021, 268, 1526-1532.	1.8	4
449	Alzheimerâ€™s Disease Neuropathological Comorbidities are Common in the Younger-Old. Journal of Alzheimer's Disease, 2021, 79, 389-400.	1.2	44
450	Quantitative Measurement of Cerebrospinal Fluid Amyloid-Î² Species by Mass Spectrometry. Journal of Alzheimer's Disease, 2021, 79, 573-584.	1.2	13
451	Hypothalamic-Bulbar MRI Hyperintensity in Anti-IgLON5 Disease with Serum-Restricted Antibodies: A Case Report and Systematic Review of Literature. Journal of Alzheimer's Disease, 2021, 79, 683-691.	1.2	6
452	Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. Lancet Neurology, The, 2021, 20, 107-116.	4.9	62
453	High-Contrast InÂVivo Imaging of Tau Pathologies in Alzheimerâ€™s and Non-Alzheimerâ€™s Disease Tauopathies. Neuron, 2021, 109, 42-58.e8.	3.8	157
454	Genetics of Progressive Supranuclear Palsy: A Review. Journal of Parkinson's Disease, 2021, 11, 93-105.	1.5	22
455	Automated Categorization of Parkinsonian Syndromes Using <scp>Magnetic Resonance Imaging</scp> in a Clinical Setting. Movement Disorders, 2021, 36, 460-470.	2.2	27
456	Connected speech in progressive supranuclear palsy: a possible role in differential diagnosis. Neurological Sciences, 2021, 42, 1483-1490.	0.9	3
457	Conventional Magnetic Resonance Imaging in the Diagnosis of Parkinsonian Disorders: A <scp>Metaâ€Analysis</scp>. Movement Disorders Clinical Practice, 2021, 8, 217-223.	0.8	7
458	Language impairment in progressive supranuclear palsy and corticobasal syndrome. Journal of Neurology, 2021, 268, 796-809.	1.8	41
459	Atypical Parkinsonâ€™s diseases: progressive supranuclear palsy and corticobasal degeneration. , 2021, , 193-247.		0
460	Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimerâ€™s Disease and Other Dementias. Journal of Alzheimer's Disease, 2021, 79, 819-832.	1.2	6

#	Article	IF	Citations
463	Atypical parkinsonism, parkinsonism-plus syndromes and secondary parkinsonian disorders. , 2021, , 249-295.e17.		0
464	Risk of dementia in APOE Îµ4 carriers is mitigated by a polygenic risk score. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12229.	1.2	16
465	A diagnostic strategy for Parkinsonian syndromes using quantitative indices of DAT SPECT and MIBG scintigraphy: an investigation using the classification and regression tree analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1833-1841.	3.3	15
467	Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants. Brain Communications, 2021, 3, fcab206.	1.5	12
468	Ophthalmological findings in movement disorders. Annals of Movement Disorders, 2021, 4, 10.	0.3	0
469	FTLD Treatment: Current Practice and Future Possibilities. Advances in Experimental Medicine and Biology, 2021, 1281, 297-310.	0.8	9
470	Natural History, Phenotypic Spectrum, and Discriminative Features of Multisystemic RFC1 Disease. Neurology, 2021, 96, e1369-e1382.	1.5	93
471	PET and SPECT Imaging of Neurodegenerative Diseases. , 2021, , 1309-1334.		0
472	Parkinsonian Dementias. , 2021, , 91-117.		0
475	Reply: Two heterozygous progranulin mutations in progressive supranuclear palsy. Brain, 2021, 144, e28-e28.	3.7	2
476	Cutaneous sensory and autonomic denervation in progressive supranuclear palsy. Neuropathology and Applied Neurobiology, 2021, 47, 653-663.	1.8	7
477	Autonomic disorders in Parkinson disease: Disrupted hypothalamic connectivity as revealed from resting-state functional magnetic resonance imaging. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 182, 211-222.	1.0	3
478	Impaired meningeal lymphatic drainage in patients with idiopathic Parkinsonâ€™s disease. Nature Medicine, 2021, 27, 411-418.	15.2	160
479	The hippocampal region is necessary for text comprehension and memorization: a combined VBM/DTI study in neuropsychological patients. Brain Imaging and Behavior, 2021, 15, 2367-2376.	1.1	1
480	LRRK2 and survival in progressive supranuclear palsy. Lancet Neurology, The, 2021, 20, 83-84.	4.9	3
481	Predicting loss of independence and mortality in frontotemporal lobar degeneration syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 737-744.	0.9	18
482	The â€œzig-zagâ€•sign in progressive supranuclear palsy â€“ The slowness of vertical saccades was the clue. Parkinsonism and Related Disorders, 2021, 83, 6-7.	1.1	0
483	Deciphering the saccade velocity profile of progressive supranuclear palsy: A sign of latent cerebellar/brainstem dysfunction?. Clinical Neurophysiology, 2021, , .	0.7	2

#	Article	IF	Citations
484	Cerebrospinal fluid N-224 tau helps discriminate Alzheimerâ€™s disease from subjective cognitive decline and other dementias. Alzheimer's Research and Therapy, 2021, 13, 38.	3.0	12
485	The â€œhypointense substantia nigraâ€•sign. A novel MRI marker of progressive supranuclear palsy. Journal of the Neurological Sciences, 2021, 421, 117286.	0.3	1
486	Disease course and treatment patterns in progressive supranuclear palsy: A real-world study. Journal of the Neurological Sciences, 2021, 421, 117293.	0.3	9
487	Advances in neuroimaging to support translational medicine in dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 263-270.	0.9	12
489	Comparison of 6-[18F]FDOPA PET with Nigrosome 1 detection in patients with parkinsonism. EJNMMI Research, 2021, 11, 16.	1.1	3
490	Cerebellar rTMS in PSP: a Double-Blind Sham-Controlled Study Using Mobile Health Technology. Cerebellum, 2021, 20, 662-666.	1.4	11
491	Distinct Vestibular Evoked Myogenic Potentials in Patients With Parkinson Disease and Progressive Supranuclear Palsy. Frontiers in Neurology, 2020, 11, 598763.	1.1	3
492	A Novel Approach for Cognitive Clustering of Parkinsonisms through Affinity Propagation. Algorithms, 2021, 14, 49.	1.2	7
493	Enablers to Exercise Participation in Progressive Supranuclear Palsy: Health Professional Perspectives. Frontiers in Neurology, 2020, 11, 635341.	1.1	3
494	The Role of Frontal Assessment Battery and Frontal Lobe Single-Photon Emission Computed Tomography in the Differential Diagnosis of Progressive Supranuclear Palsy Variants and Corticobasal Syndromeâ€”A Pilot Study. Frontiers in Neurology, 2021, 12, 630153.	1.1	7
495	A Systematic Review of Apathy and Depression in Progressive Supranuclear Palsy. Journal of Geriatric Psychiatry and Neurology, 2022, 35, 280-292.	1.2	12
496	Molecular Processing of Tau Protein in Progressive Supranuclear Palsy: Neuronal and Glial Degeneration. Journal of Alzheimer's Disease, 2021, 79, 1517-1531.	1.2	8
497	Profiling Inflammatory Extracellular Vesicles in Plasma and Cerebrospinal Fluid: An Optimized Diagnostic Model for Parkinsonâ€™s Disease. Biomedicines, 2021, 9, 230.	1.4	12
498	Application of Cerebrospinal Fluid AT(N) Framework on the Diagnosis of AD and Related Cognitive Disorders in Chinese Han Population. Clinical Interventions in Aging, 2021, Volume 16, 311-323.	1.3	9
499	Iron accumulation in the oculomotor nerve of the progressive supranuclear palsy brain. Scientific Reports, 2021, 11, 2950.	1.6	3
500	Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimerâ€™s Disease and Other Neurological Disorders. Frontiers in Neuroscience, 2021, 15, 647783.	1.4	17
501	Genetic pleiotropy and the shared pathological features of corticobasal degeneration and progressive supranuclear palsy: a case report and a review of the literature. Neurocase, 2021, 27, 120-128.	0.2	2
502	Mechanisms of Neurodegeneration in Various Forms of Parkinsonismâ€”Similarities and Differences. Cells, 2021, 10, 656.	1.8	25

#	Article	IF	Citations
503	Diffusion tensor imaging analysis in three progressive supranuclear palsy variants. Journal of Neurology, 2021, 268, 3409-3420.	1.8	12
504	Integrated 18F-T807 Tau PET, Structural MRI, and Plasma Tau in Tauopathy Neurodegenerative Disorders. Frontiers in Aging Neuroscience, 2021, 13, 646440.	1.7	13
505	National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome. Neurology, 2021, 96, 848-863.	1.5	149
506	Molecular Imaging Approaches in Dementia. Radiology, 2021, 298, 517-530.	3.6	27
507	Cerebellar ataxia in progressive supranuclear palsy: a clinico-pathological case report. Acta Neurologica Belgica, 2021, 121, 599-602.	0.5	0
508	Cognitive and behavioral profile of progressive supranuclear palsy and its phenotypes. Journal of Neurology, 2021, 268, 3400-3408.	1.8	12
509	Alpha-synuclein seeds in olfactory mucosa and cerebrospinal fluid of patients with dementia with Lewy bodies. Brain Communications, 2021, 3, fcab045.	1.5	37
510	First symptom guides diagnosis and prognosis in neurodegenerative diseasesâ€"a retrospective study of autopsy proven cases. European Journal of Neurology, 2021, 28, 1801-1811.	1.7	11
511	Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimer's Research and Therapy, 2021, 13, 68.	3.0	117
513	Genotypeâ€"Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review. Movement Disorders, 2021, 36, 1499-1510.	2.2	22
514	Diagnostic value of video-oculography in progressive supranuclear palsy: a controlled study in 100 patients. Journal of Neurology, 2021, 268, 3467-3475.	1.8	5
517	GABAergic cortical network physiology in frontotemporal lobar degeneration. Brain, 2021, 144, 2135-2145.	3.7	24
518	Two heterozygous progranulin mutations in progressive supranuclear palsy. Brain, 2021, 144, e27-e27.	3.7	9
519	Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration. JAMA Network Open, 2021, 4, e211290.	2.8	12
521	Midbrain atrophy related to parkinsonism in a non-coding repeat expansion disorder: five cases of spinocerebellar ataxia type 31 with nigrostriatal dopaminergic dysfunction. Cerebellum and Ataxias, 2021, 8, 11.	1.9	3
522	Central nystagmus in progressive supranuclear palsy: A neglected clinical feature?. Parkinsonism and Related Disorders, 2021, 84, 15-22.	1.1	0
524	Phonemic fluency quantity and quality: Comparing patients with PSP, Parkinson's disease and focal frontal and subcortical lesions. Neuropsychologia, 2021, 153, 107772.	0.7	7
525	Laboratoryâ€Supported Multiple System Atrophy beyond Autonomic Function Testing and Imaging: A Systematic Review by the <scp>MoDiMSA Study Group</scp>. Movement Disorders Clinical Practice, 2021, 8, 322-340.	0.8	7

#	Article	IF	Citations
526	The role of noradrenaline in cognition and cognitive disorders. Brain, 2021, 144, 2243-2256.	3.7	81
527	Multiparametric magnetic resonance imaging and positron emission tomography findings in neurodegenerative diseases: Current status and future directions. Neuroradiology Journal, 2021, 34, 263-288.	0.6	4
528	Association of PSP phenotypes with survival: A brain-bank study. Parkinsonism and Related Disorders, 2021, 84, 77-81.	1.1	16
529	Neuroinflammation predicts disease progression in progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 769-775.	0.9	40
530	Zebrafish Models to Study New Pathways in Tauopathies. International Journal of Molecular Sciences, 2021, 22, 4626.	1.8	6
531	Quantitative evaluation of oculomotor disturbances in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2021, 85, 63-68.	1.1	6
532	Distinctive regional asymmetry in dopaminergic and serotoninergic dysfunction in degenerative Parkinsonisms. Journal of the Neurological Sciences, 2021, 423, 117363.	0.3	5
533	Neuroimaging in Frontotemporal Dementia: Heterogeneity and Relationships with Underlying Neuropathology. Neurotherapeutics, 2021, 18, 728-752.	2.1	30
534	The final diagnoses of patients with clinically suspected atypical parkinsonian syndromes. Parkinsonism and Related Disorders, 2021, 85, 57-58.	1.1	1
535	Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease. Alzheimer's Research and Therapy, 2021, 13, 86.	3.0	19
536	Gait analysis may distinguish progressive supranuclear palsy and Parkinson disease since the earliest stages. Scientific Reports, 2021, 11, 9297.	1.6	16
537	Early suspicion of progressive supranuclear palsy using dopamine transporter imaging: an illustrative case presenting with levodopa-responsive parkinsonism. Neurological Sciences, 2021, 42, 3435-3437.	0.9	1
538	Machine learningâ€based decision tree classifier for the diagnosis of progressive supranuclear palsy and corticobasal degeneration. Neuropathology and Applied Neurobiology, 2021, 47, 931-941.	1.8	22
539	Identification of multiple system atrophy mimicking Parkinsonâ€™s disease or progressive supranuclear palsy. Brain, 2021, 144, 1138-1151.	3.7	24
540	Functional Connectome in Parkinsonâ€™s Disease and Parkinsonism. Current Neurology and Neuroscience Reports, 2021, 21, 24.	2.0	14
541	Utility of Multi-Modal MRI for Differentiating of Parkinson's Disease and Progressive Supranuclear Palsy Using Machine Learning. Frontiers in Neurology, 2021, 12, 648548.	1.1	25
542	Phonemic Verbal Fluency and Midbrain Atrophy in Progressive Supranuclear Palsy. Journal of Alzheimer's Disease, 2021, 80, 1669-1674.	1.2	5
544	Gene-Environment Interactions in Progressive Supranuclear Palsy. Frontiers in Neurology, 2021, 12, 664796.	1.1	1

#	Article	IF	Citations
545	Clinical Features Observed in General Practice Associated With the Subsequent Diagnosis of Progressive Supranuclear Palsy. Frontiers in Neurology, 2021, 12, 637176.	1.1	9
546	Spatial attention and spatial short term memory in PSP and Parkinson's disease. Cortex, 2021, 137, 49-60.	1.1	7
547	A novel diagnostic marker for progressive supranuclear palsy targeting atrophy of the subthalamic nucleus. Journal of the Neurological Sciences, 2021, 423, 117366.	0.3	3
548	DescribePSP and ProPSP: German Multicenter Networks for Standardized Prospective Collection of Clinical Data, Imaging Data, and Biomaterials of Patients With Progressive Supranuclear Palsy. Frontiers in Neurology, 2021, 12, 644064.	1.1	3
549	Molecular Imaging of Extrapyramidal Movement Disorders With Dementia: The 4R Tauopathies. Seminars in Nuclear Medicine, 2021, 51, 275-285.	2.5	3
551	Validation of the Parkinsonâ€™s Disease Caregiver Burden Questionnaire in Progressive Supranuclear Palsy. Parkinson's Disease, 2021, 2021, 1-7.	0.6	3
552	Lactoferrin in cerebrospinal fluid and saliva is not a diagnostic biomarker for Alzheimer's disease in a mixed memory clinic population. EBioMedicine, 2021, 67, 103361.	2.7	23
553	Case Report: Barely Able to Speak, Canâ€™t Stop Echoing: Echolalic Dynamic Aphasia in Progressive Supranuclear Palsy. Frontiers in Aging Neuroscience, 2021, 13, 635896.	1.7	2
554	In vivo coupling of dendritic complexity with presynaptic density in primary tauopathies. Neurobiology of Aging, 2021, 101, 187-198.	1.5	17
555	Environmental Risk Factors for Progressive Supranuclear Palsy. Journal of Movement Disorders, 2021, 14, 103-113.	0.7	8
556	Radiomics on routine T1-weighted MRI can delineate Parkinsonâ€™s disease from multiple system atrophy and progressive supranuclear palsy. European Radiology, 2021, 31, 8218-8227.	2.3	15
557	Cortical [<scp>¹⁸F</scp>]<scp>PI</scp>â€2620 Binding Differentiates Corticobasal Syndrome Subtypes. Movement Disorders, 2021, 36, 2104-2115.	2.2	46
558	Binding characteristics of [¹⁸F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2957-2972.	2.4	30
559	Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3872-3885.	3.3	22
560	Of Criteria and Menâ€”Diagnosing Atypical Parkinsonism: Towards an Algorithmic Approach. Brain Sciences, 2021, 11, 695.	1.1	2
561	A neurologistâ€™s perspective on serum neurofilament light in the memory clinic: a prospective implementation study. Alzheimer's Research and Therapy, 2021, 13, 101.	3.0	17
562	Dual-Phase Î²-Amyloid PET Captures Neuronal Injury and Amyloidosis in Corticobasal Syndrome. Frontiers in Aging Neuroscience, 2021, 13, 661284.	1.7	13
563	Impact of TSPO Receptor Polymorphism on [18F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders. Life, 2021, 11, 484.	1.1	11

#	Article	IF	Citations
564	Degenerative dementias: a question of syndrome or disease?. NeurologÃa (English Edition), 2021, , .	0.2	0
565	Progressive apraxia of speech: delays to diagnosis and rates of alternative diagnoses. Journal of Neurology, 2021, 268, 4752-4758.	1.8	5
566	<scp>¹²³Iâ€Metaiodobenzylguanidine</scp> Myocardial Scintigraphy in Discriminating Degenerative Parkinsonisms. Movement Disorders Clinical Practice, 2021, 8, 717-724.	0.8	3
567	Update on neuroimaging for categorization of Parkinson's disease and atypical parkinsonism. Current Opinion in Neurology, 2021, 34, 514-524.	1.8	7
568	Challenges in the diagnosis of Parkinson's disease. Lancet Neurology, The, 2021, 20, 385-397.	4.9	468
569	Clinical Utility of <scp>¹⁸Fâ€APN</scp>â€1607 Tau <scp>PET</scp> Imaging in Patients with Progressive Supranuclear Palsy. Movement Disorders, 2021, 36, 2314-2323.	2.2	41
570	Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. Brain, 2021, 144, 2826-2836.	3.7	65
571	Skeletal muscle loss and body composition in progressive supranuclear palsy: A retrospective cross-sectional study. PLoS ONE, 2021, 16, e0253079.	1.1	5
572	Existing statistical measures and techniques in detecting and evaluating progressive supranuclear palsy, its phenotypes by using MRI modalities: A Review. Materials Today: Proceedings, 2021, , .	0.9	0
573	Sensorimotor Cough Dysfunction Is Prevalent and Pervasive in Progressive Supranuclear Palsy. Movement Disorders, 2021, 36, 2624-2633.	2.2	10
574	Gait Analysis in Progressive Supranuclear Palsy Phenotypes. Frontiers in Neurology, 2021, 12, 674495.	1.1	8
575	Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database. Frontiers in Neurology, 2021, 12, 571800.	1.1	14
576	Digital Speech Analysis in Progressive Supranuclear Palsy and Corticobasal Syndromes. Journal of Alzheimer's Disease, 2021, 82, 33-45.	1.2	12
577	RT001 in Progressive Supranuclear Palsyâ€"Clinical and In-Vitro Observations. Antioxidants, 2021, 10, 1021.	2.2	9
578	A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech. Nature Communications, 2021, 12, 3452.	5.8	34
579	Progressive Supranuclear Palsy: Improvement in Cognitive-Behavioral Disturbances and Motor-Function Disabilities Following Treatment With Antidepressants and Cholinesterase Inhibitors. Cureus, 2021, 13, e15641.	0.2	0
580	Exploring the Connection between Porphyromonas gingivalis and Neurodegenerative Diseases: A Pilot Quantitative Study on the Bacterium Abundance in Oral Cavity and the Amount of Antibodies in Serum. Biomolecules, 2021, 11, 845.	1.8	14
581	Neuromelanin-sensitive magnetic resonance imaging in disease differentiation for parkinsonism or neurodegenerative disease affecting the basal ganglia. Parkinsonism and Related Disorders, 2021, 87, 75-81.	1.1	11

#	Article	IF	Citations
582	Prevalence and Characteristics of Polyneuropathy in Atypical Parkinsonian Syndromes: An Explorative Study. Brain Sciences, 2021, 11, 879.	1.1	1
583	Differentiating PSP from MSA using MR planimetric measurements: a systematic review and meta-analysis. Journal of Neural Transmission, 2021, 128, 1497-1505.	1.4	7
584	Motor Speech Disorders and Communication Limitations in Progressive Supranuclear Palsy. American Journal of Speech-Language Pathology, 2021, 30, 1361-1372.	0.9	12
585	Caregiver strain in progressive supranuclear palsy and corticobasal syndromes. Journal of Neural Transmission, 2021, 128, 1611-1621.	1.4	3
586	Neuropsychological Profiles of Patients with Progressive Apraxia of Speech and Aphasia. Journal of the International Neuropsychological Society, 2022, 28, 441-451.	1.2	1
587	Progressive supranuclear palsy: diagnosis and management. Practical Neurology, 2021, 21, 376-383.	0.5	12
588	Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care. Frontiers in Neurology, 2021, 12, 694872.	1.1	29
589	Language Disorder in Progressive Supranuclear Palsy and Corticobasal Syndrome: Neural Correlates and Detection by the MLSE Screening Tool. Frontiers in Aging Neuroscience, 2021, 13, 675739.	1.7	11
590	FDG-PET patterns associated with ideomotor apraxia and imitation apraxia in patients with corticobasal syndrome. Parkinsonism and Related Disorders, 2021, 88, 96-101.	1.1	4
591	Neither a Novel Tau Proteinopathy nor an Expansion of a Phenotype: Reappraising Clinicopathology-Based Nosology. International Journal of Molecular Sciences, 2021, 22, 7292.	1.8	7
593	The clinical spectrum of multisystem proteinopathy: Data from a neurodegenerative cohort. Journal of the Neurological Sciences, 2021, 426, 117478.	0.3	3
594	Coming to Terms with a Conundrum: A Case of Primary Progressive Apraxia of Speech due to Corticobasal Degeneration?. Case Reports in Neurology, 2021, 13, 483-489.	0.3	0
595	The Genetic Landscape of Parkinsonism-Related Dystonias and Atypical Parkinsonism-Related Syndromes. International Journal of Molecular Sciences, 2021, 22, 8100.	1.8	3
596	Evaluation of [¹⁸F]-JNJ-64326067-AAA tau PET tracer in humans. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 3302-3313.	2.4	15
597	Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy. Movement Disorders, 2021, 36, 2669-2675.	2.2	4
598	FRONTotemporal dementia Incidence European Research Studyâ€"FRONTIERS: Rationale and design. Alzheimer's and Dementia, 2022, 18, 498-506.	0.4	12
599	Ultrasensitive techniques and protein misfolding amplification assays for biomarker-guided reconceptualization of Alzheimerâ€™s and other neurodegenerative diseases. Expert Review of Neurotherapeutics, 2021, 21, 949-967.	1.4	4
600	Does the Antiâ€Tau Strategy in Progressive Supranuclear Palsy Need to Be Reconsidered? <scp>No</scp>. Movement Disorders Clinical Practice, 2021, 8, 1038-1040.	0.8	5

#	Article	IF	Citations
601	Novel Therapies for Parkinsonian Syndromesâ€“Recent Progress and Future Perspectives. Frontiers in Molecular Neuroscience, 2021, 14, 720220.	1.4	6
602	Primary Progressive Aphasia Presenting With Neuropsychiatric Symptoms. Journal of Geriatric Psychiatry and Neurology, 2022, 35, 574-579.	1.2	1
603	Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies. Nature Reviews Neurology, 2021, 17, 601-620.	4.9	41
604	Faster Region-Based Convolutional Neural Network in the Classification of Different Parkinsonism Patterns of the Striatum on Maximum Intensity Projection Images of [18F]FP-CIT Positron Emission Tomography. Diagnostics, 2021, 11, 1557.	1.3	5
605	Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 158-168.	0.9	7
606	Clinical features of autopsy-confirmed multiple system atrophy in the Mayo Clinic Florida brain bank. Parkinsonism and Related Disorders, 2021, 89, 155-161.	1.1	12
607	Understanding fatigue in progressive supranuclear palsy. Scientific Reports, 2021, 11, 16926.	1.6	2
608	Cellular and pathological heterogeneity of primary tauopathies. Molecular Neurodegeneration, 2021, 16, 57.	4.4	85
609	Development of parkinsonism after long-standing cervical dystonia â€“ A cohort. Journal of the Neurological Sciences, 2021, 427, 117477.	0.3	10
610	Molecular pathology and synaptic loss in primary tauopathies: an 18F-AV-1451 and 11C-UCB-J PET study. Brain, 2022, 145, 340-348.	3.7	21
611	Cerebrospinal Fluid Amyloid-Î² Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2021, 83, 179-190.	1.2	6
612	Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease. Neurology, 2021, 97, .	1.5	50
613	Neurodegenerative movement disorders: An epigenetics perspective and promise for the future. Neuropathology and Applied Neurobiology, 2021, 47, 897-909.	1.8	16
614	Semi-automated assessment of the principal diffusion direction in the corpus callosum: differentiation of idiopathic normal pressure hydrocephalus from neurodegenerative diseases. Journal of Neurology, 2022, 269, 1978-1988.	1.8	5
615	Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 68-74.	0.9	39
617	Metabolic and Structural Signatures of Speech and Language Impairment in Corticobasal Syndrome: A Multimodal PET/MRI Study. Frontiers in Neurology, 2021, 12, 702052.	1.1	10
618	Evaluation of [18F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies. Brain Communications, 2021, 3, fcab190.	1.5	36
619	Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nature Medicine, 2021, 27, 1451-1457.	15.2	63

#	Article	IF	Citations
620	Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. Neurology, 2021, 97, e1681-e1694.	1.5	60
621	â€œParkinsonâ€™s diseaseâ€•on the way to progressive supranuclear palsy: a review on PSP-parkinsonism. Neurological Sciences, 2021, 42, 4927-4936.	0.9	10
622	Seizure prevalence in neurodegenerative diseasesâ€”a study of autopsy proven cases. European Journal of Neurology, 2022, 29, 12-18.	1.7	6
623	Bodies in the Novel Infinite Jest. Frontiers in Psychology, 2021, 12, 539555.	1.1	0
624	The evaluation of the swallow tail sign in patients with parkinsonism and gait disorders. Journal of the Neurological Sciences, 2021, 428, 117581.	0.3	3
625	Strategy Adherence: A Specific and Rapidly Progressive Deficit in Progressive Supranuclear Palsy. Movement Disorders Clinical Practice, 2021, 8, 1272-1274.	0.8	1
626	Clinical Significance of Applause Sign in Patients with Progressive Supranuclear Palsy. Canadian Journal of Neurological Sciences, 2022, 49, 809-812.	0.3	1
627	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurology, The, 2021, 20, 739-752.	4.9	220
628	Structure-based classification of tauopathies. Nature, 2021, 598, 359-363.	13.7	409
629	Progressive supranuclear palsy with marked ventricular dilatation mimicking normal pressure hydrocephalus. Neurological Sciences, 2022, 43, 1783-1790.	0.9	5
630	Ocular Motor Abnormalities in Anti-IgLON5 Disease. Frontiers in Immunology, 2021, 12, 753856.	2.2	10
631	Differentiating neurodegenerative parkinsonian syndromes using vestibular evoked myogenic potentials and balance assessment. Clinical Neurophysiology, 2021, 132, 2808-2819.	0.7	2
632	Tau and MAPT genetics in tauopathies and synucleinopathies. Parkinsonism and Related Disorders, 2021, 90, 142-154.	1.1	26
633	Psychometric properties of the Beck Depression Inventoryâ€Ⅱ in progressive supranuclear palsy. Brain and Behavior, 2021, 11, e2344.	1.0	11
634	Severity of Downgaze Palsy in the Context of Disease Duration Could Estimate Survival Duration in Patients With Progressive Supranuclear Palsy. Frontiers in Neurology, 2021, 12, 736784.	1.1	2
635	Development of Î±-Synuclein Real-Time Quaking-Induced Conversion as a Diagnostic Method for Î±-Synucleinopathies. Frontiers in Aging Neuroscience, 2021, 13, 703984.	1.7	12
636	Coâ€Occurrence of Apathy and Impulsivity in Progressive Supranuclear Palsy. Movement Disorders Clinical Practice, 2021, 8, 1225-1233.	0.8	6
637	Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy. Movement Disorders, 2021, 36, 2207-2208.	2.2	0

#	Article	IF	Citations
638	Diagnostic contribution and therapeutic perspectives of transcranial magnetic stimulation in dementia. Clinical Neurophysiology, 2021, 132, 2568-2607.	0.7	85
639	Parkinsonism and tremor syndromes. Journal of the Neurological Sciences, 2022, 433, 120018.	0.3	9
640	Neuropathology of progressive supranuclear palsy after treatment with tilavonemab. Lancet Neurology, The, 2021, 20, 786-787.	4.9	9
641	Laboratory based assessment of gait and balance impairment in patients with progressive supranuclear palsy. Journal of the Neurological Sciences, 2021, 429, 118054.	0.3	4
642	Sleep disturbances in the speech-language variant of progressive supranuclear palsy. Parkinsonism and Related Disorders, 2021, 91, 9-12.	1.1	4
643	Altered network stability in progressive supranuclear palsy. Neurobiology of Aging, 2021, 107, 109-117.	1.5	8
644	Amyotrophic lateral sclerosis features predict TDP-43 pathology in frontotemporal lobar degeneration. Neurobiology of Aging, 2021, 107, 11-20.	1.5	1
645	Design and evaluation of directional antenna for shoe-mounted sensor for position identification of elderly wanderer. Sensing and Bio-Sensing Research, 2021, 34, 100451.	2.2	4
646	Behavioral Abnormalities and Cognitive Impairment in Rare Dementia Syndromes, Progressive Supranuclear Palsy, Huntington Disease and Sporadic Creutzfeldt-Jakob Disease. , 2022, , 115-130.		0
647	Neurodegenerative Motor Conditions. , 2022, , 106-114.		0
648	Effects of Lee Silverman Voice Treatment (LSVT LOUD) on Swallowing in Patients with Progressive Supranuclear Palsy: A Pilot Study. Progress in Rehabilitation Medicine, 2021, 6, n/a.	0.3	5
649	Epidemiology of atypical parkinsonian syndromes. Tzu Chi Medical Journal, 2022, 34, 169.	0.4	5
650	Subtypes of PSP and prognosis: A retrospective analysis. Annals of Indian Academy of Neurology, 2021, 24, 56.	0.2	5
651	Cerebrospinal Fluid Î±-Synuclein Species in Cognitive and Movements Disorders. Brain Sciences, 2021, 11, 119.	1.1	14
652	Characteristics and progression of patients with frontotemporal dementia in a regional memory clinic network. Alzheimer's Research and Therapy, 2021, 13, 19.	3.0	25
653	Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2259-2271.	3.3	10
654	Cognitive reserve hypothesis in frontotemporal dementia: A FDG-PET study. NeuroImage: Clinical, 2021, 29, 102535.	1.4	13
655	Immediate Effects of Sensorimotor Training in Airway Protection (smTAP) on Cough Outcomes in Progressive Supranuclear Palsy: A Feasibility Study. Dysphagia, 2022, 37, 74-83.	1.0	9

#	Article	IF	Citations
656	When it is not primary progressive aphasia: A scoping review of spoken language impairment in other neurodegenerative dementias. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12205.	1.8	17
658	Metabolic positron-emission tomography/magnetic resonance imaging in primary progressive aphasia and frontotemporal lobar degeneration subtypes: Reassessment of expected [18F]-fluorodeoxyglucose uptake patterns. World Journal of Nuclear Medicine, 2021, 20, 294-304.	0.3	3
659	Semantic fluency predicts gait velocity in PSP. Annals of Indian Academy of Neurology, 2021, 24, 896.	0.2	2
660	A Modified Progressive Supranuclear Palsy Rating Scale. Movement Disorders, 2021, 36, 1203-1215.	2.2	13
661	Atypical Parkinsonism. , 2017, , 141-169.		1
662	LRP10 variants in progressive supranuclear palsy. Neurobiology of Aging, 2020, 94, 311.e5-311.e10.	1.5	6
663	Progressive supranuclear palsy: Advances in diagnosis and management. Parkinsonism and Related Disorders, 2020, 73, 105-116.	1.1	55
664	Isolated parkinsonism is an atypical presentation of GRN and C9orf72 gene mutations. Parkinsonism and Related Disorders, 2020, 80, 73-81.	1.1	13
665	Primary progressive apraxia of speech: A further piece in the progressive supranuclear/corticobasal degeneration spectrum jigsaw. Parkinsonism and Related Disorders, 2020, 81, 219-220.	1.1	2
666	Sex-related differences in the relationship between Î²-amyloid and cognitive trajectories in older adults.. Neuropsychology, 2020, 34, 835-850.	1.0	9
667	New advances in tau imaging in parkinsonism. International Review of Psychiatry, 2017, 29, 628-635.	1.4	7
668	Redefining the multidimensional clinical phenotypes of frontotemporal lobar degeneration syndromes. Brain, 2020, 143, 1555-1571.	3.7	94
669	Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD. Journal of Neuropathology and Experimental Neurology, 2020, 79, 296-304.	0.9	35
682	Colonic transit time in progressive supranuclear palsy and Parkinson's disease. Neurology and Clinical Neuroscience, 2021, 9, 91-94.	0.2	2
683	Impact of the cerebrospinal fluid-mask algorithm on the diagnostic performance of 123I-Ioflupane SPECT: an investigation of parkinsonian syndromes. EJNMMI Research, 2019, 9, 85.	1.1	3
684	Progressive Supranuclear Palsy, Corticobasal Degeneration, and Multiple System Atrophy. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 919-935.	0.4	12
685	Survival Analysis in Primary Progressive Apraxia of Speech and Agrammatic Aphasia. Neurology: Clinical Practice, 2021, 11, 249-255.	0.8	9
686	Cohort Study in Parkinsonism. Neurology: Clinical Practice, 2021, 11, e407-e413.	0.8	9

#	Article	IF	Citations
687	Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. Neurology, 2020, 95, e3026-e3035.	1.5	31
688	Increased Signal in the Superior Cerebellar Peduncle of Patients with Progressive Supranuclear Palsy. Journal of Movement Disorders, 2019, 12, 166-171.	0.7	3
689	Clinical Milestones Preceding the Diagnosis of Multiple System Atrophy and Progressive Supranuclear Palsy: A Retrospective Cohort Study. Journal of Movement Disorders, 2019, 12, 177-183.	0.7	6
690	Automated Brainstem Segmentation Detects Differential Involvement in Atypical Parkinsonian Syndromes. Journal of Movement Disorders, 2020, 13, 39-46.	0.7	16
691	Progressive Supranuclear Palsy with Predominant Cerebellar Ataxia. Journal of Movement Disorders, 2020, 13, 20-26.	0.7	18
692	The Non-Motor Symptom Profile of Progressive Supranuclear Palsy. Journal of Movement Disorders, 2020, 13, 118-126.	0.7	15
693	The continuum between neurodegeneration, brain plasticity, and movement: a critical appraisal. Reviews in the Neurosciences, 2020, 31, 723-742.	1.4	30
694	The Differential Diagnosis of Parkinsonâ€™s Disease. , 0, , 109-128.		20
695	Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes. Deutsches Ärzteblatt International, 2019, 116, 747-754.	0.6	27
696	Validation of the Korean Version of the Questionnaire for Impulsive-Compulsive Disorders in		

#	Article	IF	Citations
706	Energy expenditure, body composition and dietary habits in progressive supranuclear palsy. Journal of Neurology, 2021, , 1.	1.8	1
707	Application of the <scp>mPSPRS</scp> to the Salerno Cohort and a Comparison Between <scp>PSPâ€RS</scp> and <scp>vPSP</scp>. Movement Disorders, 2021, 36, 2449-2451.	2.2	0
708	Eyeâ€ofâ€theâ€tiger sign with an unexpected pathological diagnosis. Movement Disorders Clinical Practice, 2022, 9, 98-103.	0.8	0
709	Neurofilament light chain and Î±-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes. Npj Parkinson's Disease, 2021, 7, 93.	2.5	45
710	Pragmatic Approach on Neuroimaging Techniques for the Differential Diagnosis of Parkinsonisms. Movement Disorders Clinical Practice, 2022, 9, 6-19.	0.8	21
711	Autopsy Validation of Progressive Supranuclear Palsyâ€Predominant Speech/Language Disorder Criteria. Movement Disorders, 2022, 37, 213-218.	2.2	6
712	NeurozobrazovacÃ-kazuistika. Neurologie Pro Praxi, 2017, 18, 201-201.	0.0	0
713	The Phenotypic Variants of Patients with Progressive Supranuclear Palsy. Noropsikiyatri Arsivi, 2020, 57, 61-64.	0.7	0
719	Computer Aided Feature Extraction inÂtheÂPaper Version of Luriaâ€™s Alternating Series Test in Progressive Supranuclear Palsy. Advances in Intelligent Systems and Computing, 2019, , 561-570.	0.5	3
720	Progressive supranuclear palsy responding to intravenous thiamine: superimposed Wernickeâ€™s encephalopathy?. BMJ Case Reports, 2018, 2018, bcr-2018-226170.	0.2	0
721	Diagnostic Dilemmas. , 2019, , 473-532.		0
722	Parkinson-Plus-Syndrome. Springer Reference Medizin, 2019, , 1-10.	0.0	0
723	Transient Hypersomnolence Provoked by Metoclopramide in a Patient with Degenerative Parkinsonism. Journal of Movement Disorders, 2019, 12, 60-62.	0.7	1
724	Translational Neurology of Slow Saccades. Contemporary Clinical Neuroscience, 2019, , 221-254.	0.3	0
725	Neurodegenerative Diseases: Progressive Supranuclear Palsy (PSP)â€“Cortico-Basal Degeneration (CBD). , 2019, , 973-985.		1
726	Neuropsychology of Movement Disorders and Motor Neuron Disease: Parkinsonâ€™s Disease, Progressive Supranuclear Palsy, Essential Tremor, Huntingtonâ€™s Disease, and Amyotrophic Lateral Sclerosis. , 2019, , 415-440.		0
727	Methods (1): Participants and Test Methods. , 2019, , 21-49.		0
728	Bilateral INO in PSP. Annals of Indian Academy of Neurology, 2020, 23, 235.	0.2	1

#	Article	IF	Citations
730	Progressive supranuclear palsy as differential diagnosis of Parkinson's disease in the elderly. Revista Espanola De Geriatria Y Gerontologia, 2019, 54, 251-256.	0.2	0
731	Clinical Updates and Recent Developments in Neuro-Ophthalmology. , 2020, , 201-249.		0
737	Estudio de registro de pacientes con desÃ³rdenes del movimiento con autoprescripciÃ³n de formas no estandarizadas de cannabis. Experiencia de un centro especializado en movimientos anormales de Buenos Aires. Neurologia Argentina, 2020, 12, 165-171.	0.1	0
738	Are Some Eponyms in Neurology Used Correctly?. Russian Neurological Journal, 2020, 25, 45-50.	0.1	0
740	Proton magnetic resonance spectroscopy in frontotemporal lobar degeneration-related syndromes. Neurobiology of Aging, 2022, 111, 64-70.	1.5	10
741	Characterizing Anarthria to Facilitate Neurological Diagnosis: A Case Illustration. Perspectives of the ASHA Special Interest Groups, 0, , 1-7.	0.4	0
742	Early Impairment of Chopsticks Skills in Parkinsonism Suggests Progressive Supranuclear Palsy.		

#	Article	IF	Citations
759	PET and SPECT Imaging in Atypical Parkinsonian Syndromes. , 2021, , 729-757.		0
760	Comparative Performance of 99mTc-TRODAT-1 SPECT/CT and 18F-FDOPA PET/CT Imaging in Patients With Parkinsonâ€™s Disease, Parkinson-Plus Syndrome, and Essential Tremor. Clinical Nuclear Medicine, 2021, 46, 95-102.	0.7	10
762	18F-AV-1451 positron emission tomography in neuropathological substrates of corticobasal syndrome. Brain, 2021, 144, 266-277.	3.7	7
763	Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration. Neurology: Clinical Practice, 2021, 11, 105-116.	0.8	5
764	Early perfusion and dopamine transporter imaging using F-FP-CIT PET/CT in patients with parkinsonism. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 360-372.	1.0	15
766	Commentary on PSP Subtypes in India. Annals of Indian Academy of Neurology, 2021, 24, 3-4.	0.2	0
767	PET imaging in dementia. , 2021, , .		0
768	Cardiovascular autonomic dysfunction is associated with executive dysfunction and poorer quality of life in progressive supranuclear palsy-Richardsonâ€™s syndrome. Journal of Clinical Neuroscience, 2021, , .	0.8	1
769	InÂVivo ¹⁸F-Flortaucipir PET Does Not Accurately Support the Staging of Progressive Supranuclear Palsy. Journal of Nuclear Medicine, 2022, 63, 1052-1057.	2.8	9
770	A Neurologist's Practical Approach to Cognitive Impairment. Seminars in Neurology, 2021, 41, 686-698.	0.5	0
771	Parkinson's disease and parkinsonism: Clinicopathological discrepancies on diagnosis in three patients. Neuropathology, 2021, 41, 450-456.	0.7	1
772	The role of noncoding RNAs in Parkinsonâ€™s disease: biomarkers and associations with pathogenic pathways. Journal of Biomedical Science, 2021, 28, 78.	2.6	45
774	Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach. Npj Parkinson's Disease, 2021, 7, 107.	2.5	11
775	Measuring social cognition in frontotemporal lobar degeneration: a clinical approach. Journal of Neurology, 2021, , 1.	1.8	2
776	Segmental Alterations of the Corpus Callosum in Progressive Supranuclear Palsy: A Multiparametric Magnetic Resonance Imaging Study. Frontiers in Aging Neuroscience, 2021, 13, 720634.	1.7	2
777	Approach to the Patient with Gait Disturbance. Seminars in Neurology, 2021, 41, 717-730.	0.5	0
779	Umbilical cord blood stem cells transplantation in a patient with severe progressive supranuclear palsy: a case report. Journal of Medical Case Reports, 2021, 15, 574.	0.4	1
780	In Vivo<scp>¹⁸Fâ€APN</scp>â€1607 Tau <scp>Positron Emission Tomography</scp> Imaging in <scp>MAPT</scp> Mutations: Crossâ€Sectional and Longitudinal Findings. Movement Disorders, 2022, 37, 525-534.	2.2	8

#	Article	IF	Citations
781	Neuropsychology Assessment in Dementia and Neurodegenerative Disease. , 2022, , 247-255.		0
782	Case 9: Progressive Supranuclear Palsy: Richardson Syndrome and Parkinsonian Variants. , 2022, , 45-50.		0
783	The role of cardiovascular autonomic failure in the differential diagnosis of Î±-synucleinopathies. Neurological Sciences, 2022, 43, 187-198.	0.9	5
784	Exosomal miRNA as peripheral biomarkers in Parkinson's disease and progressive supranuclear palsy: A pilot study. Parkinsonism and Related Disorders, 2021, 93, 77-84.	1.1	36
785	Dynamic Aphasia as a Variant of Frontotemporal Dementia. Cognitive and Behavioral Neurology, 2021, 34, 303-318.	0.5	2
786	The contribution of behavioral features to caregiver burden in FTLD spectrum disorders. Alzheimer's and Dementia, 2022, 18, 1635-1649.	0.4	9
787	An Unusual Presentation of Progressive Supranuclear Palsy. Neurology India, 2021, 69, 1789.	0.2	2
788	Central Nervous System Imaging in Movement Disorders. , 2021, , .		0
790	Brain volume patterns in corticobasal syndrome versus idiopathic Parkinson's disease. Journal of Neuroimaging, 2022, , .	1.0	1
791	Concordance of regional hypoperfusion by pCASL MRI and 15O-water PET in frontotemporal dementia: Is pCASL an efficacious alternative?. NeuroImage: Clinical, 2022, 33, 102950.	1.4	6
792	Neuroimaging Pearls from the <scp>MDS</scp> Congress Video Challenge. Part 2: Acquired Disorders. Movement Disorders Clinical Practice, 2022, 9, 311-325.	0.8	2
793	Ex vivo MRI and histopathology detect novel iron-rich cortical inflammation in frontotemporal lobar degeneration with tau versus TDP-43 pathology. NeuroImage: Clinical, 2022, 33, 102913.	1.4	17
794	Dopaminergic imaging in degenerative parkinsonisms, an established clinical diagnostic tool. Journal of Neurochemistry, 2023, 164, 346-363.	2.1	10
795	Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimerâ€™s disease, frontotemporal dementia and progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 651-658.	0.9	64
796	Lewy body disease or diseases with Lewy bodies?. Npj Parkinson's Disease, 2022, 8, 3.	2.5	26
797	Role of Apolipoprotein E in the Clinical Profile of Atypical Parkinsonian Syndromes. Alzheimer Disease and Associated Disorders, 2022, 36, 36-43.	0.6	3
798	Frequently Asked Questions on Autoimmune Encephalitis and Related Disorders. , 2022, , 630-655.		1
799	Abnormal Movements in Neurological Autoimmune Disorders. , 2022, , 545-562.		0

#	Article	IF	Citations
800	Training high level balance and stepping responses in atypical progressive supranuclear palsy: a case report. Physiotherapy Theory and Practice, 2023, 39, 1071-1082.	0.6	3
801	Increased Intrathecal B and Plasma Cells in Patients With Anti-IgLON5 Disease. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	8
802	Digital Phenotyping in Clinical Neurology. Seminars in Neurology, 2022, 42, 048-059.	0.5	11
803	Signature laminar distributions of pathology in frontotemporal lobar degeneration. Acta Neuropathologica, 2022, 143, 363-382.	3.9	12
804	Longitudinal changes of early motor and cognitive symptoms in progressive supranuclear palsy: the OxQUIP study. BMJ Neurology Open, 2022, 4, e000214.	0.7	5
805	Perspective: Balance Assessments in Progressive Supranuclear Palsy: Lessons Learned. Frontiers in Neurology, 2022, 13, 801291.	1.1	4
806	Is the Phenotype Designation by PSP-MDS Criteria Stable Throughout the Disease Course and Consistent With Tau Distribution?. Frontiers in Neurology, 2022, 13, 827338.	1.1	5
807	The Strengths and Obstacles in the Differential Diagnosis of Progressive Supranuclear Palsyâ€"Parkinsonism Predominant (PSP-P) and Multiple System Atrophy (MSA) Using Magnetic Resonance Imaging (MRI) and Perfusion Single Photon Emission Computed Tomography (SPECT). Diagnostics, 2022, 12, 385.	1.3	11
808	Uncovering clinical and radiological asymmetry in progressive supranuclear palsyâ€"Richardsonâ€™s syndrome. Neurological Sciences, 2022, , 1.	0.9	1
809	A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy. Molecular Medicine Reports, 2022, 25, .	1.1	11
810	Diffusion microstructure imaging in progressive supranuclear palsy: reduced axonal volumes in the superior cerebellar peduncles, dentato-rubro-thalamic tracts, ventromedial thalami, and frontomesial white matter. Cerebral Cortex, 2022, 32, 5628-5636.	1.6	6
811	Examining the presence and nature of delusions in Alzheimerâ€™s disease and frontotemporal dementia syndromes. International Journal of Geriatric Psychiatry, 2022, 37, .	1.3	4
812	Differential Diagnosis of Rare Subtypes of Progressive Supranuclear Palsy and PSP-Like Syndromesâ€"Infrequent Manifestations of the Most Common Form of Atypical Parkinsonism. Frontiers in Aging Neuroscience, 2022, 14, 804385.	1.7	9
813	Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial. BMJ Open, 2021, 11, e055019.	0.8	4
815	Aetiology and pathophysiology of neurodegenerative disorders. , 2022, , 1-16.		0
816	Sleep architecture in progressive supranuclear palsy: A video-polysomnography study. Annals of Indian Academy of Neurology, 2022, 25, 858.	0.2	1
817	Corticobasal syndrome as a phenotype of various neurodegenerative disorders: a case series. Annals of Clinical and Experimental Neurology, 2022, 16, 64-70.	0.1	0
819	Tractography of supplementary motor area projections in progressive speech apraxia and aphasia. NeuroImage: Clinical, 2022, 34, 102999.	1.4	11

#	Article	IF	Citations
820	Dopamine Transporter Imaging for Frontotemporal Lobar Degeneration With Motor Neuron Disease. Frontiers in Neuroscience, 2022, 16, 755211.	1.4	6
822	A holistic approach to evaluating Parkinsonâ€™s disease, using the Delphi method: a linear evaluation index. Arquivos De Neuro-Psiquiatria, 2022, 80, 145-152.	0.3	0
823	A replication study, systematic review and meta-analysis of automated image-based diagnosis in parkinsonism. Scientific Reports, 2022, 12, 2763.	1.6	8
824	Serum NfL and CHI3L1 for ALS and parkinsonian disorders in the process of diagnosis. Journal of Neural Transmission, 2022, 129, 301-309.	1.4	6
826	Dopaminergic Correlates of Regional Cerebral Blood Flow in Parkinsonian Disorders. Movement Disorders, 2022, 37, 1235-1244.	2.2	4
827	Clinical Trial Development in Frontotemporal Lobar Degeneration. , 2022, , 216-231.		0
828	PMCA-Based Detection of Prions in the Olfactory Mucosa of Patients With Sporadic Creutzfeldtâ€“Jakob Disease. Frontiers in Aging Neuroscience, 2022, 14, 848991.	1.7	4
829	Differential diagnosis of parkinsonism based on deep metabolic imaging indices. Journal of Nuclear Medicine, 2022, , jnumed.121.263029.	2.8	9
830	Evaluation of Brain SPECT with 99mTc-TRODAT-1 in the Differential Diagnosis of Parkinsonism. Parkinson's Disease, 2022, 2022, 1-10.	0.6	1
831	Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nature Communications, 2022, 13, 1362.	5.8	34
832	Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration. Brain, 2022, 145, 2769-2784.	3.7	15
833	Difficulties in differential diagnosis of chronic tick-borne encephalitis and progressive supranuclear palsy. Russian Neurological Journal, 2022, 27, 88-93.	0.1	1
834	The Added Value of Cerebrospinal Fluid Neurofilament Light Chain to Existing Diagnostic Methods and Biomarkers in a Mixed Memory Clinic Cohort of Consecutive Patients. Journal of Alzheimer's Disease Reports, 2022, 6, 121-127.	1.2	2
835	Neurofilament Light Chain Levels in Frontotemporal Dementia and Progressive Supranuclear Palsy: A Systematic Review. Journal of Alzheimer's Disease, 2022, 87, 131-140.	1.2	5
836	What Is the Brainstem Control of Locomotion?. Neurology, 2022, 98, 446-451.	1.5	4
837	Pathologically Verified Corticobasal Degeneration Mimicking Richardson's Syndrome Coexisting with Clinically and Radiologically Shuntâ€Responsive Normal Pressure Hydrocephalus. Movement Disorders Clinical Practice, 2022, 9, 508-515.	0.8	2
838	Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism. Movement Disorders, 2022, 37, 1245-1255.	2.2	8
839	Anti-IgLON5 Disease â€“ The Current State of Knowledge and Further Perspectives. Frontiers in Immunology, 2022, 13, 852215.	2.2	19

#	Article	IF	Citations
840	Pain in atypical parkinsonism, vascular parkinsonism, and Parkinsonâ€™s disease. Neurological Sciences, 2022, 43, 4797-4802.	0.9	2
841	The changing landscape of neuroimaging in frontotemporal lobar degeneration: from group-level observations to single-subject data interpretation. Expert Review of Neurotherapeutics, 2022, 22, 179-207.	1.4	8
842	Validity of cingulateâ€“precuneusâ€“temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimerâ€™s Disease. Journal of Neurology, 2022, 269, 4440-4451.	1.8	3
843	A neurodegenerative disease landscape of rare mutations in Colombia due to founder effects. Genome Medicine, 2022, 14, 27.	3.6	16
844	Development of a sensitive trial-ready poly(GP) CSF biomarker assay forC9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 761-771.	0.9	12
845	Reduction in Volume of Nucleus Basalis of Meynert Is Specific to Parkinsonâ€™s Disease and Progressive Supranuclear Palsy but Not to Multiple System Atrophy. Frontiers in Aging Neuroscience, 2022, 14, 851788.	1.7	7
846	Normative Data for Brainstem Structures, the Midbrain-to-Pons Ratio, and the Magnetic Resonance Parkinsonism Index. American Journal of Neuroradiology, 2022, 43, 707-714.	1.2	3
847	Protracted course progressive supranuclear palsy. European Journal of Neurology, 2022, 29, 2220-2231.	1.7	8
848	The Non-motor Symptoms, Disability Progression, and Survival Analysis of Atypical Parkinsonism: Case Series from Eastern India and Brief Review of Literature. Journal of Neurosciences in Rural Practice, 0, , .	0.3	0
849	Do Patients with Progressive Supranuclear Palsy Have Episodic Memory Impairment? A Systematic Review. Movement Disorders Clinical Practice, 2022, 9, 436-445.	0.8	4
851	Therapeutic strategies for tauopathies and drug repurposing as a potential approach. Biochemical Pharmacology, 2022, 198, 114979.	2.0	7
852	The Free and Cued Selective Reminding Test: Discriminative Values in a Naturalistic Cohort. Journal of Alzheimer's Disease, 2022, 87, 887-899.	1.2	1
853	Utility of 18F FDG-PET in Parkinsonism in an African population. ENeurologicalSci, 2022, 27, 100399.	0.5	1
855	Tufted astrocyteâ€like glia in two autopsy cases of multiple system atrophy: Is it a concomitant neurodegenerative disorder with multiple system atrophy and progressive supranuclear palsy?. Neuropathology, 2022, 42, 74-81.	0.7	3
856	Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. Translational Neurodegeneration, 2021, 10, 50.	3.6	32
857	Therapeutic Application of rTMS in Atypical Parkinsonian Disorders. Behavioural Neurology, 2021, 2021, 1-12.	1.1	0
858	Diagnostic Performance of the Magnetic Resonance Parkinsonism Index in Differentiating Progressive Supranuclear Palsy from Parkinsonâ€™s Disease: An Updated Systematic Review and Meta-Analysis. Diagnostics, 2022, 12, 12.	1.3	5
859	Depression and Apathy across Different Variants of Progressive Supranuclear Palsy. Movement Disorders Clinical Practice, 2022, 9, 212-217.	0.8	8

#	Article	IF	Citations
860	Brainstem Biomarkers of Clinical Variant and Pathology in Progressive Supranuclear Palsy. Movement Disorders, 2022, 37, 702-712.	2.2	14
861	Alpha-synuclein oligomers and small nerve fiber pathology in skin are potential biomarkers of Parkinsonâ€™s disease. Npj Parkinson's Disease, 2021, 7, 119.	2.5	19
863	Peripapillary retinal nerve fiber layer thinning in patients with progressive supranuclear palsy. Journal of Neurology, 2022, 269, 3216-3225.	1.8	6
864	Differentiating Progressive Supranuclear Palsy and Parkinson's Disease With Head-Mounted Displays. Frontiers in Neurology, 2021, 12, 791366.	1.1	4
865	Retinal thinning in progressive supranuclear palsy: differences with healthy controls and correlation with clinical variables. Neurological Sciences, 2022, 43, 4803-4809.	0.9	15
866	Progressive supranuclear palsy with predominant frontal presentation exhibiting progressive nonfluent aphasia due to crossed aphasia. Neuropathology, 2022, , .	0.7	1
868	Development and Validation of Automated <scp>Magnetic Resonance</scp> Parkinsonism Index 2.0 to Distinguish <scp>Progressive Supranuclear Palsyâ€Parkinsonism</scp> From <scp>Parkinson's Disease</scp>. Movement Disorders, 2022, 37, 1272-1281.	2.2	17
869	¹⁸F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy. Journal of Nuclear Medicine, 2022, , jnumed.121.262854.	2.8	8
870	Clinicoradiological features in progressive supranuclear palsy comorbid with argyrophilic grains. Movement Disorders Clinical Practice, 2022, 9, 484-488.	0.8	3
871	Optimization of cognitive assessment in Parkinsonisms by applying artificial intelligence to a comprehensive screening test. Npj Parkinson's Disease, 2022, 8, 42.	2.5	5
872	A data-driven model of brain volume changes in progressive supranuclear palsy. Brain Communications, 2022, 4, .	1.5	12
873	RT-QuIC and Related Assays for Detecting and Quantifying Prion-like Pathological Seeds of Î±-Synuclein. Biomolecules, 2022, 12, 576.	1.8	7
874	Differential diagnosis between Parkinson's disease and atypical parkinsonism based on gait and postural instability: Artificial intelligence using an enhanced weight voting ensemble model. Parkinsonism and Related Disorders, 2022, 98, 32-37.	1.1	3
886	Commentary on PSP subtypes in India. Annals of Indian Academy of Neurology, 2021, 24, 3.	0.2	0
887	Advanced diffusion imaging to track progression in Parkinsonâ€™s disease, multiple system atrophy, and progressive supranuclear palsy. NeuroImage: Clinical, 2022, 34, 103022.	1.4	12
888	Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. JAMA Network Open, 2022, 5, e229588.	2.8	18
889	Tau protein quantification in skin biopsies differentiates tauopathies from alpha-synucleinopathies. Brain, 2022, 145, 2755-2768.	3.7	8
890	Eye tracking identifies biomarkers in Î±-synucleinopathies versus progressive supranuclear palsy. Journal of Neurology, 2022, 269, 4920-4938.	1.8	6

#	Article	IF	Citations
891	Adverse Events of Physiotherapy Interventions in Parkinsonian Patients. Movement Disorders Clinical Practice, 2022, 9, 744-750.	0.8	3
892	Is MRPI 2.0 More Useful than MRPI and M/P Ratio in Differential Diagnosis of PSP-P with Other Atypical Parkinsonisms?. Journal of Clinical Medicine, 2022, 11, 2701.	1.0	7
893	Cognitive and affective disturbances in patients with Parkinson's disease: Perspectives for classifying of motor/neuropsychiatric subtypes. Neuroscience Letters, 2022, 781, 136675.	1.0	12
894	Plasma microRNAs as a Potential Biomarker for Identification of Progressive Supranuclear Palsy. Diagnostics, 2022, 12, 1204.	1.3	2
895	Epileptic Seizures and Right-Sided Hippocampal Swelling as Presenting Symptoms of Anti-IgLON5 Disease: A Case Report and Systematic Review of the Literature. Frontiers in Neurology, 2022, 13, .	1.1	5
896	Diffusion tractography of superior cerebellar peduncle and dentatorubrothalamic tracts in two autopsy confirmed progressive supranuclear palsy variants: Richardson syndrome and the speech-language variant. NeuroImage: Clinical, 2022, 35, 103030.	1.4	8
897	Biomarker A+Tâ^': is this Alzheimerâ€™s disease or not? A combined CSF and pathology study. Brain, 2023, 146, 1166-1174.	3.7	12
898	MAPT gene mutation in familiar progressive supranuclear palsy, a case report. Neurology Perspectives, 2022, 2, 184-186.	0.2	0
899	Abnormal metabolic covariance patterns associated with multiple system atrophy and progressive supranuclear palsy. Physica Medica, 2022, 98, 131-138.	0.4	9
900	Combined CSF Î±-SYN RT-QuIC, CSF NFL and midbrain-pons planimetry in degenerative parkinsonisms: From bedside to bench, and back again. Parkinsonism and Related Disorders, 2022, 99, 33-41.	1.1	12
901	The Indirect Impact of COVID-19 on Major Clinical Outcomes of People With Parkinson's Disease or Parkinsonism: A Cohort Study. Frontiers in Neurology, 2022, 13, .	1.1	4
902	Decoding the dopamine transporter imaging for the differential diagnosis of parkinsonism using deep learning. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2798-2811.	3.3	15
903	Genotypeâ€“Phenotype Correlation in Progressive Supranuclear Palsy Syndromes: Clinical and Radiological Similarities and Specificities. Frontiers in Neurology, 2022, 13, 861585.	1.1	3
904	Clinical Aspects of the Differential Diagnosis of Parkinsonâ€™s Disease and Parkinsonism. Journal of		

#	Article	IF	Citations
912	Brain MRI-Based Artificial Intelligence Software in Patients with Neurodegenerative Diseases: Current Status. Journal of the Korean Society of Radiology, 2022, 83, 473.	0.1	2
913	Recent Advances in Frontotemporal Dementia. Canadian Journal of Neurological Sciences, 2023, 50, 485-494.	0.3	2
914	Automated Detection of Speech Timing Alterations in Autopsy-Confirmed Nonfluent/Agrammatic Variant Primary Progressive Aphasia. Neurology, 2022, 99, .	1.5	17
915	Dopamine transporter imaging in progressive supranuclear palsy: Severe but nonspecific to subtypes. Acta Neurologica Scandinavica, 2022, 146, 237-245.	1.0	5
916	Episodic memory in progressive supranuclear palsy: a neuropsychological and neuroimaging study. Neurological Sciences, 0, , .	0.9	1
917	Factors associated with mortality in early stages of parkinsonism. Npj Parkinson's Disease, 2022, 8, .	2.5	4
918	Detection and differentiation of ataxic and hypokinetic dysarthria in cerebellar ataxia and parkinsonian disorders via wave splitting and integrating neural networks. PLoS ONE, 2022, 17, e0268337.	1.1	7
919	Probable progressive supranuclear palsy in a patient with chronic schizophrenia: A case report. Experimental and Therapeutic Medicine, 2022, 24, .	0.8	1
920	The Application of Deep Brain Stimulation for Progressive Supranuclear Palsy: A Systematic Review. Frontiers in Neurology, 0, 13, .	1.1	3
921	Diffusion tensor imaging for the differential diagnosis of Parkinsonism by machine learning. Biomedical Journal, 2023, 46, 100541.	1.4	4
922	Parkinsonism in idiopathic normal pressure hydrocephalus: is it time for defining a clinical tetrad?. Neurological Sciences, 2022, 43, 5201-5205.	0.9	6
923	Differential diagnosis of patients with atypical Parkinsonian syndrome using 18F-FDG and 18F-FP CIT PET: A report of five cases. Radiology Case Reports, 2022, 17, 2765-2770.	0.2	1
924	Outils dâ€™imagerie dans les maladies neurodÃ©gÃ©nÃ©ratives. , 2022, , 73-85.		0
925	Maladies apparentÃ©es Ã la maladie de Parkinson idiopathique. , 2022, , 253-265.		0
926	Resting state functional brain networks associated with emotion processing in frontotemporal lobar degeneration. Molecular Psychiatry, 2022, 27, 4809-4821.	4.1	4
927	A novel diagnostic approach for patients with adult-onset dystonia. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 1039-1048.	0.9	3
928	Incremental diagnostic value of 18F-Fluetemetamol PET in differential diagnoses of Alzheimerâ€™s Disease-related neurodegenerative diseases from an unselected memory clinic cohort. Scientific Reports, 2022, 12, .	1.6	3
929	Investigational therapeutics for the treatment of progressive supranuclear palsy. Expert Opinion on Investigational Drugs, 2022, 31, 813-823.	1.9	1

#	Article	IF	Citations
932	Morphometric imaging and quantitative susceptibility mapping as complementary tools in the diagnosis of parkinsonisms. European Journal of Neurology, 2022, 29, 2944-2955.	1.7	4
933	A case presenting with a major depressive episode with palilalia and difficulty opening eyes as prodromal symptoms of progressive supranuclear palsy. , 2022, 1, .		0
934	Disease modification in Parkinsonism: obstacles and ways forward. Journal of Neural Transmission, 0, , .	1.4	7
935	Oculomotor abnormalities and its association with sleep stages in progressive supranuclear palsy. Sleep Medicine, 2022, , .	0.8	0
937	A Reproducible Deep-Learning-Based Computer-Aided Diagnosis Tool for Frontotemporal Dementia Using MONAI and Clinica Frameworks. Life, 2022, 12, 947.	1.1	5
938	Performance of Î±Synuclein RT-QuIC in relation to neuropathological staging of Lewy body disease. Acta Neuropathologica Communications, 2022, 10, .	2.4	31
939	FDG PET in the differential diagnosis of degenerative parkinsonian disorders: usefulness of voxel-based analysis in clinical practice. Neurological Sciences, 0, , .	0.9	2
940	Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment. Brain Communications, 2022, 4, .	1.5	11
941	Circulating miRNAs in progressive supranuclear palsy: Recent evidence and future challenges. Parkinsonism and Related Disorders, 2022, 101, 18-19.	1.1	0
942	Tau-PET and multimodal imaging in clinically atypical multiple system atrophy masquerading as progressive supranuclear palsy. Parkinsonism and Related Disorders, 2022, 101, 9-14.	1.1	2
943	Parkinsonian Syndromes in Motor Neuron Disease: A Clinical Study. Frontiers in Aging Neuroscience, 0, 14, .	1.7	7
944	Bedside Assessment of Autonomic Dysfunction in Multiple System Atrophy. Journal of Parkinson's Disease, 2022, 12, 2277-2281.	1.5	3
945	Clinical Spectrum of Tauopathies. Frontiers in Neurology, 0, 13, .	1.1	9
946	Automated volumetric determination of high R₂[*] regions in substantia nigra: A feasibility study of quantifying substantia nigra atrophy in progressive supranuclear palsy. NMR in Biomedicine, 2022, 35, .	1.6	1
947	The Burden of Progressive Supranuclear Palsy on Patients, Caregivers, and Healthcare Systems by PSP Phenotype: A Cross-Sectional Study. Frontiers in Neurology, 0, 13, .	1.1	2
948	Risk of <scp>SARSâ€CoV</scp>â€2 infection, hospitalization, and death for <scp>COVID</scp>â€19 in people with Parkinson disease or parkinsonism over a 15â€month period: A cohort study. European Journal of Neurology, 2022, 29, 3205-3217.	1.7	7
949	Frontal Atrophy and Executive Dysfunction Relate to Complex Numbers Impairment in Progressive Supranuclear Palsy. Journal of Alzheimer's Disease, 2022, 88, 1553-1566.	1.2	2
950	The Significance of Asymmetry in the Assessment of Brain Perfusion in Atypical Tauopathic Parkinsonian Syndromes. Diagnostics, 2022, 12, 1671.	1.3	0

#	Article	IF	Citations
951	Differences in aphasia syndromes between progressive supranuclear palsyâ€“Richardsonâ€™s syndrome, behavioral variant frontotemporal dementia and Alzheimerâ€™s dementia. Journal of Neural Transmission, 0, , .	1.4	1
952	An autopsy case of progressive supranuclear palsy. Pallidoâ€nigroâ€luysian type with argyrophilic grains clinically presenting with personality and behavioral changes. Neuropathology, 2022, 42, 447-452.	0.7	2
953	Characterization and diagnostic potential of R2* in early-stage progressive supranuclear palsy variants. Parkinsonism and Related Disorders, 2022, 101, 43-48.	1.1	5
954	Genetics of progressive supranuclear palsy in a Chinese population. Neurobiology of Disease, 2022, 172, 105819.	2.1	2
955	Frontotemporal lobar degeneration. , 2023, , 337-360.		0
956	Update on the Cognitive Presentations of iNPH for Clinicians. Frontiers in Neurology, 0, 13, .	1.1	0
957	Magnetic Resonance Planimetry in the Differential Diagnosis between Parkinsonâ€™s Disease and Progressive Supranuclear Palsy. Brain Sciences, 2022, 12, 949.	1.1	5
958	Neurocognitive health of older adults experiencing homelessness in Oakland, California. Frontiers in Neurology, 0, 13, .	1.1	3
959	Increased Subcortical Sodium Levels in Patients with Progressive Supranuclear Palsy. Biomedicines, 2022, 10, 1728.	1.4	1
960	Longâ€Duration Progressive Supranuclear Palsy: Clinical Course and Pathological Underpinnings. Annals of Neurology, 2022, 92, 637-649.	2.8	13
961	Progressive supranuclear palsy and corticobasal degeneration: novel clinical concepts and advances in biomarkers. Arquivos De Neuro-Psiquiatria, 2022, 80, 126-136.	0.3	5
962	Neuropathology and emerging biomarkers in corticobasal syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 919-929.	0.9	27
963	Olfactory swab sampling optimization for Î±-synuclein aggregate detection in patients with Parkinsonâ€™s disease. Translational Neurodegeneration, 2022, 11, .	3.6	16
964	Unravelling the etiology of sporadic late-onset cerebellar ataxia in a cohort of 205 patients: a prospective study. Journal of Neurology, 2022, 269, 6354-6365.	1.8	11
965	The New Zealand Genetic Frontotemporal Dementia Study (FTDGeNZ): a longitudinal study of pre-symptomatic biomarkers. Journal of the Royal Society of New Zealand, 2023, 53, 511-531.	1.0	1
967	Headache-Associated Phantosmia as a Harbinger of Lewy Body Dementia. Journal of Neuropsychiatry and Clinical Neurosciences, 2023, 35, 92-97.	0.9	0
968	CSF levels of SNAP-25 are increased early in Creutzfeldt-Jakob and Alzheimerâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 1059-1065.	0.9	13
969	Qualitative evaluation of the Rey-Osterrieth Complex Figure Test in patients with progressive supranuclear palsy. Clinical Neuropsychologist, 0, , 1-14.	1.5	0

#	Article	IF	Citations
970	The neurophysiological effect of NMDA-R antagonism of frontotemporal lobar degeneration is conditional on individual GABA concentration. Translational Psychiatry, 2022, 12, .	2.4	0
971	Rainwater Charitable Foundation criteria for the neuropathologic diagnosis of progressive supranuclear palsy. Acta Neuropathologica, 2022, 144, 603-614.	3.9	35
972	Epidemiology of Progressive Supranuclear Palsy: Real World Data from the Second Largest Health Plan in Israel. Brain Sciences, 2022, 12, 1126.	1.1	7
973	A Review on the Clinical Diagnosis of Multiple System Atrophy. Cerebellum, 2023, 22, 825-839.	1.4	6
974	Incongruences Between Facial Expression and Self-Reported Emotional Reactivity in Frontotemporal Dementia and Related Disorders. Journal of Neuropsychiatry and Clinical Neurosciences, 2023, 35, 192-201.	0.9	1
976	Striatal dopaminergic lesions contributed to the disease severity in progressive supranuclear palsy. Frontiers in Aging Neuroscience, 0, 14, .	1.7	3
977	Macroscopic diagnostic clue for parkinsonism. Neuropathology, 2022, 42, 394-419.	0.7	3
978	Realâ€life benefits of intrajejunal levodopa infusion therapy in four patients with the parkinsonian variant of progressive supranuclear palsy: A 1â€year followâ€up data report. Brain and Behavior, 2022, 12, .	1.0	2
979	Prevalence and associated factors of frailty and sarcopenia in multiple system atrophy and progressive supranuclear palsy: a cross-sectional study. Neurological Sciences, 0, , .	0.9	1
980	Selective tau seeding assays and isoform-specific antibodies define neuroanatomic distribution of progressive supranuclear palsy pathology arising in Alzheimerâ€™s disease. Acta Neuropathologica, 2022, 144, 789-792.	3.9	1
981	Cortical atrophy distinguishes idiopathic normal-pressure hydrocephalus from progressive supranuclear palsy: A machine learning approach. Parkinsonism and Related Disorders, 2022, 103, 7-14.	1.1	9
982	Additive value of [18F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 423-434.	3.3	10
983	Effect of therapeutic exercise on the balance of patients with progressive supranuclear palsy: A pilot study. Frontiers in Neurology, 0, 13, .	1.1	2
984	I'm looking through you: Mentalizing in frontotemporal dementia and progressive supranuclear palsy. Cortex, 2022, 155, 373-389.	1.1	2
985	Relationship between CSF tau biomarkers and structural brain MRI measures in frontotemporal lobar degeneration. Journal of the Neurological Sciences, 2022, 442, 120415.	0.3	2
986	Functional connectivity to the premotor cortex maps onto longitudinal brain neurodegeneration in progressive apraxia of speech. Neurobiology of Aging, 2022, 120, 105-116.	1.5	6
987	Longitudinal Monitoring of Progressive Supranuclear Palsy using <scp>Bodyâ€Worn</scp> Movement Sensors. Movement Disorders, 2022, 37, 2263-2271.	2.2	10
988	Autonomic dysfunction in progressive supranuclear palsy. Journal of Neurology, 2023, 270, 109-129.	1.8	4

#	Article	IF	Citations
989	A Guide for the Differential Diagnosis of Multiple System Atrophy in Clinical Practice. Journal of Parkinson's Disease, 2022, 12, 2015-2027.	1.5	4
990	A Machine Learningâ€“Based Approach to Discrimination of Tauopathies Using [<scp>¹⁸F</scp>]<scp>PMâ€PBB3 PET</scp> Images. Movement Disorders, 2022, 37, 2236-2246.	2.2	10
991	Alzheimerâ€™s Disease Diagnosis Based on the Amyloid, Tau, and Neurodegeneration Scheme (ATN) in a Real-Life Multicenter Cohort of General Neurological Centers. Journal of Alzheimer's Disease, 2022, 90, 419-432.	1.2	3
992	TARDBP mutations in a cohort of Italian patients with Parkinsonâ€™s disease and atypical parkinsonisms. Frontiers in Aging Neuroscience, 0, 14, .	1.7	5
993	Toward More Accessible Fully Automated 3D Volumetric MRI Decision Trees for the Differential Diagnosis of Multiple System Atrophy, Related Disorders, and Age-Matched Healthy Subjects. Cerebellum, 2023, 22, 1098-1108.	1.4	3
994	Reduced phonemic fluency in progressive supranuclear palsy is due to dysfunction of dominant BA6. Frontiers in Aging Neuroscience, 0, 14, .	1.7	0
995	Tau seeding activity in various regions of down syndrome brain assessed by two novel assays. Acta Neuropathologica Communications, 2022, 10, .	2.4	4
997	Impact of Amyloid and Tau PET on Changes in Diagnosis and Patient Management. Neurology, 2023, 100, .	1.5	8
998	Interplay of tau and functional network connectivity in progressive supranuclear palsy: a [18F]PI-2620 PET/MRI study. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 50, 103-114.	3.3	5
999	Research trends and frontiers in exercise for movement disorders: A bibliometric analysis of global research from 2010 to 2021. Frontiers in Aging Neuroscience, 0, 14, .	1.7	1
1000	Primary progressive aphasia and motor neuron disease: A review. Frontiers in Aging Neuroscience, 0, 14, .	1.7	6
1001	Serum Uric Acid Levels in Neurodegenerative Disorders: A Cross-Sectional Study. Journal of Alzheimer's Disease, 2022, 90, 761-773.	1.2	5
1002	Nigral glucose metabolism as a diagnostic marker of neurodegenerative parkinsonian syndromes. Npj Parkinson's Disease, 2022, 8, .	2.5	5
1003	Assessment of Bioenergetic Deficits in Patients With Parkinson Disease and Progressive Supranuclear Palsy Using ³¹ P-MRSI. Neurology, 2022, 99, .	1.5	5
1004	Non-REM sleep with hypertonia in Parkinsonian Spectrum Disorders: A pilot investigation. Sleep Medicine, 2022, 100, 501-510.	0.8	5
1005	Retinal nerve fiber layer in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Frontiers in Neuroscience, 0, 16, .	1.4	0
1007	Accuracy of clinical versus oculographic detection of pathological saccadic slowing. Journal of the Neurological Sciences, 2022, 442, 120436.	0.3	1
1008	Dysphagia in progressive supranuclear palsy: A scoping review protocol. Advances in Communication and Swallowing, 2022, , 1-5.	0.2	0

#	Article	IF	Citations
1009	Annonaceae Consumption Worsens Disease Severity and Cognitive Deficits in Degenerative Parkinsonism. Movement Disorders, 2022, 37, 2355-2366.	2.2	3
1010	Differential cholinergic systemsâ€™ changes in progressive supranuclear palsy versus Parkinsonâ€™s disease: an exploratory analysis. Journal of Neural Transmission, 2022, 129, 1469-1479.	1.4	2
1011	Digital Histological Study of Neocortical Grey and White Matter Tau Burden Across Tauopathies. Journal of Neuropathology and Experimental Neurology, 2022, 81, 953-964.	0.9	2
1012	Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimerâ€™s disease and frontotemporal lobar degeneration. Alzheimer's Research and Therapy, 2022, 14, .	3.0	22
1013	Rhythmic auditory cueing in atypical parkinsonism: A pilot study. Frontiers in Neurology, 0, 13, .	1.1	2
1014	Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias. Alzheimer's Research and Therapy, 2022, 14, .	3.0	33
1015	Clinicopathological features of progressive supranuclear palsy with asymmetrical atrophy of the superior cerebellar peduncle. Neuropathology, 0, , .	0.7	0
1016	The Assessment of Subregions in the Frontal Lobe May Be Feasible in the Differential Diagnosis of Progressive Supranuclear Palsyâ€”Parkinsonism Predominant (PSP-P) and Multiple System Atrophy (MSA). Diagnostics, 2022, 12, 2421.	1.3	3
1017	Cellâ€Specific Dysregulation of Iron and Oxygen Homeostasis as a Novel Pathophysiology in <scp>PSP</scp>. Annals of Neurology, 2023, 93, 431-445.	2.8	8
1018	Reflexive and volitional saccadic eye movements and their changes in age and progressive supranuclear palsy. Journal of the Neurological Sciences, 2022, , 120482.	0.3	0
1019	Acoustic and Kinematic Assessment of Motor Speech Impairment in Patients With Suspected Four-Repeat Tauopathies. Journal of Speech, Language, and Hearing Research, 2022, 65, 4112-4132.	0.7	1
1020	Speech acoustic indices for differential diagnosis between Parkinsonâ€™s disease, multiple system atrophy and progressive supranuclear palsy. Npj Parkinson's Disease, 2022, 8, .	2.5	6
1021	Progressive Supranuclear Palsy and Corticobasal Syndrome. CONTINUUM Lifelong Learning in Neurology, 2022, 28, 1364-1378.	0.4	1
1022	Preâ€diagnostic cognitive and functional impairment in multiple sporadic neurodegenerative diseases. Alzheimer's and Dementia, 2023, 19, 1752-1763.	0.4	14
1023	Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers. JAMA Neurology, 2022, 79, 1155.	4.5	12
1024	The many faces of globular glial tauopathy: A clinical and imaging study. European Journal of Neurology, 2023, 30, 321-333.	1.7	8
1025	Neuroimaging in progressive supranuclear palsy. , 2023, , 355-397.		0
1026	Parkinson's disease and related disorders. , 2023, , 3-19.		0

#	Article	IF	Citations
1027	Sex Is the Main Determinant of Levodopa Clinical Pharmacokinetics: Evidence from a Large Series of Levodopa Therapeutic Monitoring. Journal of Parkinson's Disease, 2022, 12, 2519-2530.	1.5	7
1028	Tau seeds from patients induce progressive supranuclear palsy pathology and symptoms in primates. Brain, 2023, 146, 2524-2534.	3.7	5
1029	Clinical Correlates of Cerebrospinal Fluid 14-3-3 Protein in Non-Prion Rapid Progressive Dementia. Journal of Alzheimer's Disease, 2022, , 1-10.	1.2	0
1030	A descriptive study of Parkinson disease and atypical parkinsonisms in the Annuals of the Pathological Autopsy Cases in Japan. Neuropathology, 2023, 43, 297-305.	0.7	1
1032	Motor symptoms in genetic frontotemporal dementia: developing a new module for clinical rating scales. Journal of Neurology, 2023, 270, 1466-1477.	1.8	2
1033	Delay in the diagnosis of dementia in urban India: Role of dementia subtype and age at onset. International Journal of Geriatric Psychiatry, 2022, 37, .	1.3	2
1034	C9orf72 repeat length might influence clinical sub-phenotypes in dementia patients. Neurobiology of Disease, 2022, 175, 105927.	2.1	3
1035	Performance of [18F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy. Parkinsonism and Related Disorders, 2023, 106, 105226.	1.1	3
1036	Tau immunotherapy in Alzheimerâ€™s disease and progressive supranuclear palsy. International Immunopharmacology, 2022, 113, 109445.	1.7	5
1037	A case of non-fluent/agrammatic variant of primary progressive aphasia with logoclonia. Clinical Neurology, 2022, , .	0.0	0
1038	Oligomeric Î±-synuclein and tau aggregates in NDEVs differentiate Parkinson's disease from atypical parkinsonisms. Neurobiology of Disease, 2023, 176, 105947.	2.1	19
1039	Two pathways differentially linking tau depositions, oxidative stress, and neuronal loss to apathetic phenotypes in progressive supranuclear palsy. Journal of the Neurological Sciences, 2023, 444, 120514.	0.3	8
1040	Plasma neurofilament light chain in memory clinic practice: Evidence from a real-life study. Neurobiology of Disease, 2023, 176, 105937.	2.1	8
1041	Neurologic music therapy combined with EEG-tDCS for upper motor extremity performance in patients with corticobasal syndrome: Study protocol for a novel approach. Contemporary Clinical Trials, 2023, 125, 107058.	0.8	2
1042	QEEG Signatures are Associated with Nonmotor Dysfunctions in Parkinson's Disease and Atypical Parkinsonism: An Integrative Analysis. , 2023, 14, 204.		6
1043	Performing a short sway to distinguish Parkinsonisms. , 2022, , .		0
1044	Potential of Non-Coding RNA as Biomarkers for Progressive Supranuclear Palsy. International Journal of Molecular Sciences, 2022, 23, 14554.	1.8	1
1045	Reduction in Skeletal Muscle Mass in Progressive Supranuclear Palsy in Comparison with Parkinsonâ€™s Disease: A Preliminary Retrospective Longitudinal Study. , 2022, 1, 143-151.		0

#	Article	IF	Citations
1046	The Lived Experiences of People with Progressive Supranuclear Palsy and Their Caregivers. Neurology and Therapy, 2023, 12, 229-247.	1.4	2
1047	Diagnostic Performance and Clinical Applicability of Blood-Based Biomarkers in a Prospective Memory Clinic Cohort. Neurology, 2023, 100, e860-e873.	1.5	16
1048	Early Diagnosis of Parkinsonâ€™s Disease: Utility of Animal Models. , 0, , .		0
1049	Brain-derived tau: a novel blood-based biomarker for Alzheimerâ€™s disease-type neurodegeneration. Brain, 2023, 146, 1152-1165.	3.7	58
1050	Plasma sphingolipid abnormalities in neurodegenerative diseases. PLoS ONE, 2022, 17, e0279315.	1.1	6
1051	An optimized reference tissue method for quantification of tau protein depositions in diverse neurodegenerative disorders by PET with 18F-PM-PBB3 (18F-APN-1607). NeuroImage, 2022, 264, 119763.	2.1	9
1055	Neurophysiological consequences of synapse loss in progressive supranuclear palsy. Brain, 2023, 146, 2584-2594.	3.7	3
1056	The Use of Cerebellar Hypoperfusion Assessment in the Differential Diagnosis of Multiple System Atrophy with Parkinsonism and Progressive Supranuclear Palsy-Parkinsonism Predominant. Diagnostics, 2022, 12, 3022.	1.3	2
1058	Changing faces of mitochondrial disease: autosomal recessivePOLGdisease mimicking myasthenia gravis and progressive supranuclear palsy. BMJ Neurology Open, 2022, 4, e000352.	0.7	2
1059	Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimerâ€™s disease continuum. Molecular Neurodegeneration, 2022, 17, .	4.4	21
1060	Rapidly Progressive Corticobasal Degeneration Mimicking Brainstem Encephalitis. Movement Disorders Clinical Practice, 2023, 10, 300-306.	0.8	2
1061	<scp>Cerebrospinal Fluid</scp> Biomarkers of Synaptic Dysfunction are Altered in Parkinson's Disease and Related Disorders. Movement Disorders, 2023, 38, 267-277.	2.2	10
1063	Assessment of perfusion deficit with early phases of [18F]PI-2620 tau-PET versus [18F]flutemetamol-amyloid-PET recordings. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 1384-1394.	3.3	3
1064	CSF P-Tau181 and Other Biomarkers in Patients With Neuronal Intranuclear Inclusion Disease. Neurology, 2023, 100, .	1.5	5
1065	Tau PET imaging in progressive supranuclear palsy: a systematic review and meta-analysis. Journal of Neurology, 2023, 270, 2451-2467.	1.8	8
1066	Current Updates and Unmet Needs of Brain MRI-Based Artificial Intelligence Software for Patients With Neurodegenerative Diseases in the Republic of Korea. Investigative Magnetic Resonance Imaging, 2022, 26, 237.	0.2	0
1067	The Apraxia of Speech Rating Scale: Reliability, Validity, and Utility. American Journal of Speech-Language Pathology, 2023, 32, 469-491.	0.9	13
1068	The Rossy Progressive Supranuclear Palsy Centre: creation and initial experience. Canadian Journal of Neurological Sciences, 0, , 1-28.	0.3	1

#	Article	IF	Citations
1069	Longitudinal clinical decline and baseline predictors in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2023, 107, 105290.	1.1	2
1070	Higher prevalence of idiopathic normal pressure hydrocephalusâ€like MRI features in progressive supranuclear palsy: An imaging reminder of atypical parkinsonism. Brain and Behavior, 2023, 13, .	1.0	3
1071	Neuropsychiatric symptoms in genetic frontotemporal dementia: developing a new module for Clinical Rating Scales. Journal of Neurology, Neurosurgery and Psychiatry, 2023, 94, 357-368.	0.9	5
1072	18F-Florzolotau PET imaging captures the distribution patterns and regional vulnerability of tau pathology in progressive supranuclear palsy. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 1395-1405.	3.3	8
1073	Apathy evaluation scale-informant version in progressive supranuclear palsy: Psychometric properties and clinical correlates. Parkinsonism and Related Disorders, 2023, 107, 105293.	1.1	0
1074	Comparison of mean diffusivity, R2* relaxation rate and morphometric biomarkers for the clinical differentiation of parkinsonism. Parkinsonism and Related Disorders, 2023, 108, 105287.	1.1	2
1075	Optical coherence tomography and angiography in Alzheimer's disease and other cognitive disorders. European Journal of Ophthalmology, 2023, 33, 1706-1717.	0.7	2
1076	An autopsy case of progressive supranuclear palsy treated with monoclonal antibody against tau. Neuropathology, 2023, 43, 326-332.	0.7	2
1077	Clinical and MRI features of gait and balance disorders in neurodegenerative diseases. Journal of Neurology, 2023, 270, 1798-1807.	1.8	3
1078	PDQ-8: A Simplified and Effective Tool Measuring Life Quality in Progressive Supranuclear Palsy. Journal of Parkinson's Disease, 2022, , 1-9.	1.5	0
1079	Using Downgaze Palsy Progression Rate to Model Survival in Progressive Supranuclear Palsyâ€“<scp>Richardson</scp> Syndrome. Movement Disorders, 2023, 38, 304-312.	2.2	1
1080	Clinical, cognitive, and morphometric profiles of progressive supranuclear palsy phenotypes. Journal of Neural Transmission, 2023, 130, 97-109.	1.4	8
1081	Neuronal intranuclear inclusion disease mimicking progressive supranuclear palsy. Neurological Sciences, 0, , .	0.9	0
1082	Retinal Structure Abnormalities in Parkinsonâ€™s Disease and Atypical Parkinsonism. Biomolecules, 2023, 13, 218.	1.8	2
1083	Expanding MAPT p.V363I mutation phenotype: an overlapping of PSPâ€CBS and posterior cortical atrophy. Movement Disorders Clinical Practice, 0, , .	0.8	0
1084	Dopamine transporter SPECT imaging in Parkinsonâ€™s disease and atypical Parkinsonism: a study of 137 patients. Neurological Sciences, 2023, 44, 1613-1623.	0.9	2
1086	Why Therapeutic Trials Fail in Primary Tauopathies. Movement Disorders, 2023, 38, 545-550.	2.2	1
1087	Loss of torsional quick eye movements during head roll in progressive supranuclear palsy: aÂnew diagnostic marker. Journal of Neurology, 2023, 270, 2230-2236.	1.8	0

#	Article	IF	Citations
1088	Neuropathology of spinocerebellar ataxia type 8: Common features and unique tauopathy. Neuropathology, 0, , .	0.7	1
1089	Non-motor symptoms in multiple system atrophy: A comparative study with Parkinson's disease and progressive supranuclear palsy. Frontiers in Neurology, 0, 13, .	1.1	1
1090	Neurological update: the palliative care landscape for atypical parkinsonian syndromes. Journal of Neurology, 2023, 270, 2333-2341.	1.8	2
1091	Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy. Movement Disorders, 0, , .	2.2	1
1092	Midbrain and pons MRI shape analysis and its clinical and CSF correlates in degenerative parkinsonisms: a pilot study. European Radiology, 2023, 33, 4540-4551.	2.3	4
1093	Idiopathic Normal Pressure Hydrocephalus and Progressive Supranuclear Palsy: Two Single Entities or Neurodegenerative Overlap Syndrome? A Case Report. Medicina (Lithuania), 2023, 59, 720.	0.8	0
1094	Prevalence, Timing, and Network Localization of Emergent Visual Creativity in Frontotemporal Dementia. JAMA Neurology, 2023, 80, 377.	4.5	6
1095	The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies. Expert Opinion on Drug Discovery, 2023, 18, 515-526.	2.5	4
1096	Retinal photoreceptor layer thickness has disease specificity and distinguishes predicted FTLD-Tau from biomarker-determined Alzheimer's disease. Neurobiology of Aging, 2023, 125, 74-82.	1.5	0
1097	New insights from a multi-ethnic Asian progressive supranuclear palsy cohort. Parkinsonism and Related Disorders, 2023, 108, 105296.	1.1	4
1098	Incidence of Syndromes Associated With Frontotemporal Lobar Degeneration in 9 European Countries. JAMA Neurology, 2023, 80, 279.	4.5	15
1099	Magnetic resonance imaging modalities aid in the differential diagnosis of atypical parkinsonian syndromes. Frontiers in Neurology, 0, 14, .	1.1	0
1100	Complement system changes in blood in Parkinson's disease and progressive Supranuclear Palsy/Corticobasal Syndrome. Parkinsonism and Related Disorders, 2023, 108, 105313.	1.1	3
1101	A unified classification approach rating clinical utility of protein biomarkers across neurologic diseases. EBioMedicine, 2023, 89, 104456.	2.7	6
1102	Semantic knowledge of social interactions is mediated by the hedonic evaluation system in the brain. Cortex, 2023, 161, 26-37.	1.1	1
1103	<scp>¹⁸Fâ€Florzolotau</scp> Positron Emission Tomography Imaging of Tau Pathology in the Living Brains of Patients with Corticobasal Syndrome. Movement Disorders, 2023, 38, 579-588.	2.2	4
1104	C9ORF72 repeat expansion is not associated with atypical parkinsonism in the Serbian population. Genetika, 2022, 54, 1313-1330.	0.1	0
1105	Assessing Patients and Care Partner Ratings of Communication-Related Participation Restrictions: Insights From Degenerative Disease. American Journal of Speech-Language Pathology, 0, , 1-13.	0.9	0

#	Article	IF	Citations
1106	Quantifying Impairments in Swallowing Safety and Efficiency in Progressive Supranuclear Palsy and Parkinsonâ€™s Disease. Dysphagia, 0, , .	1.0	0
1107	Pathology vs pathogenesis: Rationale and pitfalls in the clinicopathology model of neurodegeneration. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 35-55.	1.0	0
1108	Accurate Detection of <scp>Î±â€Synuclein</scp> Seeds in Cerebrospinal Fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa) Cohort. Movement Disorders, 2023, 38, 567-578.	2.2	21
1109	Immune cell counts in cerebrospinal fluid predict cognitive function in aging and neurodegenerative disease. Alzheimer's and Dementia, 2023, 19, 3339-3349.	0.4	5
1110	Serum inflammatory cytokines levels and the correlation analyses in Parkinsonâ€™s disease. Frontiers in Cell and Developmental Biology, 0, 11, .	1.8	2
1111	<scp>LRRK2</scp> Quantification in Cerebrospinal Fluid of Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes. Movement Disorders, 2023, 38, 682-688.	2.2	0
1112	CSF AÎ²42 and AÎ²42/AÎ²40 Ratio in Alzheimerâ€™s Disease and Frontotemporal Dementias. Diagnostics, 2023, 13, 783.	1.3	4
1113	Verbal fluency tests assess global cognitive status but have limited diagnostic differentiation: evidence from a large-scale examination of six neurodegenerative diseases. Brain Communications, 2023, 5, .	1.5	5
1114	Case report: Backward gait training combined with gait-synchronized cerebellar transcranial alternating current stimulation in progressive supranuclear palsy. Frontiers in Human Neuroscience, 0, 17, .	1.0	2
1115	Wearable sensors for assessing disease severity and progression in Progressive Supranuclear Palsy. Parkinsonism and Related Disorders, 2023, 109, 105345.	1.1	4
1116	<scp>SQSTM1</scp> Mutation Presenting as a Progressive Supranuclear Palsy Mimic. Movement Disorders Clinical Practice, 2023, 10, 839-841.	0.8	0
1117	<scp> MAPT </scp> â€Associated Familial Progressive Supranuclear Palsy with Typical Corticobasal Degeneration Neuropathology: A Clinicopathological Report. Movement Disorders Clinical Practice, 2023, 10, 691-694.	0.8	0
1118	Ataxias: Hereditary, Acquired, and Reversible Etiologies. Seminars in Neurology, 2023, 43, 048-064.	0.5	0
1119	Identification of phosphorylated tau protein interactors in progressive supranuclear palsy () Tj ETQq1 1 0.784314 rgBT /Overlock 10 T dynamics, metabolic processes, and neurotransmission. Journal of Neurochemistry, 0, , .	2.1	0
1120	Redefining Bradykinesia. Movement Disorders, 2023, 38, 551-557.	2.2	12
1121	Case report: Saccadic ping-pong gaze in progressive supranuclear palsy with predominant postural instability. Frontiers in Neurology, 0, 14, .	1.1	0
1122	Comparative validation of AI and non-AI methods in MRI volumetry to diagnose Parkinsonian syndromes. Scientific Reports, 2023, 13, .	1.6	1
1123	Thioflavin S Staining and Amyloid Formation Are Unique to Mixed Tauopathies. Journal of Histochemistry and Cytochemistry, 2023, 71, 73-86.	1.3	3

#	Article	IF	Citations
1124	Pathomechanisms of cognitive impairment in progressive supranuclear palsy. Journal of Neural Transmission, 2023, 130, 481-493.	1.4	2
1125	Î±â€Synuclein Seed Amplification Assays in the Diagnosis of Synucleinopathies Using Cerebrospinal Fluidâ€"A Systematic Review and Metaâ€Analysis. Movement Disorders Clinical Practice, 2023, 10, 737-747.	0.8	9
1126	Uncovering spatiotemporal patterns of atrophy in progressive supranuclear palsy using unsupervised machine learning. Brain Communications, 2023, 5, .	1.5	2
1127	Correlations between cerebrospinal fluid homovanillic acid and dopamine transporter SPECT in degenerative parkinsonian syndromes. Journal of Neural Transmission, 2023, 130, 513-520.	1.4	0
1128	Structural and Molecular Imaging for Clinically Uncertain Parkinsonism. Seminars in Neurology, 2023, 43, 095-105.	0.5	0
1130	Correlation between the Regional Brain Volume and Glymphatic System Activity in Progressive Supranuclear Palsy. Dementia and Geriatric Cognitive Disorders, 2023, 52, 177-183.	0.7	1
1131	Nigrosome 1 visibility and its association with nigrostriatal dopaminergic loss in Parkinson's disease. European Journal of Neurology, 0, , .	1.7	0
1132	Indication for molecular testing by multiplex ligationâ€dependent probe amplification in parkinsonism. European Journal of Neurology, 0, , .	1.7	0
1133	Scale for the Assessment and Rating of Ataxia (SARA): Development of a Training Tool and Certification Program. Cerebellum, 0, , .	1.4	5
1134	Multiple system atrophy. Practical Neurology, 2023, 23, 208-221.	0.5	1
1135	The role of magnetic resonance imaging in the diff erential diagnosis of Parkinsonâ€™s disease. Russian Neurological Journal, 2023, 28, 5-12.	0.1	1
1136	Efficacy of faecal microbiota transplantation in patients with progressive supranuclear palsy-Richardson's syndrome: a phase 2, single centre, randomised clinical trial. EClinicalMedicine, 2023, 58, 101888.	3.2	6
1137	Pathomechanisms of depression in progressive supranuclear palsy. Journal of Neural Transmission, 2023, 130, 1049-1056.	1.4	1
1138	Cognitive Impairment in Neurodegenerative Movement Disorders. Seminars in Neurology, 2023, 43, 081-094.	0.5	0
1139	Advances in the Diagnosis and Management of Psychotic Symptoms in Neurodegenerative Diseases: A Narrative Review. Journal of Geriatric Psychiatry and Neurology, 0, , 089198872311643.	1.2	0
1140	Brainstem atrophy in dementia with Lewy bodies compared with progressive supranuclear palsy and Parkinsonâ€™s disease on MRI. BMC Neurology, 2023, 23, .	0.8	3
1142	SCRN1: A cerebrospinal fluid biomarker correlating with tau in Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 4609-4618.	0.4	4
1143	Progressive Supranuclear Palsy in 2022: recent developments and an eye to the future. Advances in Clinical Neuroscience & Rehabilitation: ACNR, 0, , .	0.1	0

#	Article	IF	Citations
1144	Rapidly progressive dementia with severe insomnia: an unusual case of progressive supranuclear palsy mimicking dementia with Lewy bodies. Neurological Sciences, 0, , .	0.9	0
1145	Quick computer aided differential diagnostics based on repetitive finger tapping in Parkinsonâ€™s disease and atypical parkinsonisms. Heliyon, 2023, 9, e14824.	1.4	1
1146	The evolution of diagnosis from symptom onset to death in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) compared to Parkinsonâ€™s disease (PD). Journal of Neurology, 2023, 270, 3464-3474.	1.8	2
1147	microRNA and circRNA in Parkinsonâ€™s Disease and atypical parkinsonian syndromes. Advances in Clinical Chemistry, 2023, , 83-133.	1.8	1
1148	Progression of atypical parkinsonian syndromes: PROSPECT-M-UK study implications for clinical trials. Brain, 2023, 146, 3232-3242.	3.7	5
1149	Clinical milestones as triggers for palliative care intervention in progressive Supranuclear palsy and multiple system atrophy. Journal of the Neurological Sciences, 2023, 448, 120614.	0.3	1
1150	Olfactory Bulb Volume, Olfactory Sulcus Depth in Parkinson's Disease, Atypical Parkinsonism. Movement Disorders Clinical Practice, 2023, 10, 794-801.	0.8	0
1151	Association of APOE Îµ4/Îµ4 with fluid biomarkers in patients from the PUMCH dementia cohort. Frontiers in Aging Neuroscience, 0, 15, .	1.7	2
1152	Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome. JAMA Neurology, 2023, 80, 495.	4.5	1
1153	Serum Cathepsin S Levels Do Not Show Alterations in Different Clinical, Neuropathological, or Genetic Subtypes of Frontotemporal Dementia Patients nor in Comparison to Healthy Control Individuals. Journal of Alzheimer's Disease, 2023, , 1-7.	1.2	0
1154	Association between Cognitive Impairment and Freezing of Gait in Patients with Parkinsonâ€™s Disease. Journal of Clinical Medicine, 2023, 12, 2799.	1.0	6
1155	Low clinical sensitivity and unexpectedly high incidence for neuropathologically diagnosed progressive supranuclear palsy. Journal of Neuropathology and Experimental Neurology, 2023, 82, 438-451.	0.9	4
1157	RBD and hyposmia in Moroccan patients with a synucleinopathy: prevalence and the timing of occurrence in a large cohort. Acta Neurologica Belgica, 0, , .	0.5	0
1158	Movement disorders are linked to TDP-43 burden in the substantia nigra of FTLD-TDP brain donors. Acta Neuropathologica Communications, 2023, 11, .	2.4	1
1159	Significance of clinical symptoms and red flags in early differential diagnosis of Parkinsonâ€™s disease and atypical Parkinsonian syndromes. Journal of Neural Transmission, 2023, 130, 839-846.	1.4	3
1160	Symptomatology in 4-repeat tauopathies is associated with data-driven topology of [18F]-PI-2620 tau-PET signal. NeuroImage: Clinical, 2023, 38, 103402.	1.4	6
1162	The utility of quantitative MRI parameters in discriminating progressive supranuclear palsy from Parkinsonâ€™s disease. Neurological Research, 0, , 1-7.	0.6	0
1163	Diagnosis across a cohort of â€œatypicalâ€•atypical and complex parkinsonism. Parkinsonism and Related Disorders, 2023, , 105408.	1.1	1

#	Article	IF	Citations
1177	Dystonia and Parkinsonâ€™s disease: Do they have a shared biology?. International Review of Neurobiology, 2023, , .	0.9	0
1219	Extrapyramidale StÃ¶rungen und neurodegenerative Erkrankungen. , 2023, , 127-174.		0
1235	Differentiating between common PSP phenotypes using structural MRI: a machine learning study. Journal of Neurology, 2023, 270, 5502-5515.	1.8	3
1236	Case report: Atypical Parkinsonism following SARS-CoV-2 infection. Frontiers in Neurology, 0, 14, .	1.1	1
1241	Anxiety and physical impairment in patients with central vestibular disorders. Journal of Neurology, 2023, 270, 5589-5599.	1.8	1
1254	A retrospective study of autoimmune cerebellar ataxia over a 20-year period in a single institution. Journal of Neurology, 2024, 271, 553-563.	1.8	1
1255	What Is Neurodegeneration?. , 2023, , 1-13.		0
1258	DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease. Nature Aging, 2023, 3, 1201-1209.	5.3	7
1271	Passive tau-based immunotherapy for tauopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 611-619.	1.0	1
1278	Progressive supranuclear palsy phenotypic presentation associated with anti MA2 antibody. Acta Neurologica Belgica, 0, , .	0.5	0
1281	Investigating differences in young- and late-onset progressive supranuclear palsy. Journal of Neurology, 0, , .	1.8	0
1291	Alternating unilateral blepharospasm with apraxia of eyelid opening in a patient with progressive supranuclear palsy. Neurological Sciences, 0, , .	0.9	0
1297	Neuroimaging determinants of cognitive impairment in the memory clinic: how important is the vascular burden?. Journal of Neurology, 0, , .	1.8	0
1303	Differentiating progressive supranuclear palsy from other movement disorders using transcranial sonography: a systematic review and meta-analysis. Neurological Sciences, 0, , .	0.9	0
1324	Differential Diagnosis: â€œWhat Is the Lesion?â€• , 2023, , 137-281.		0
1341	Neuroimaging correlates of postural instability in Parkinsonâ€™s disease. Journal of Neurology, 0, , .	1.8	0
1362	Progressive Supranuclear Palsy Diagnosis and Treatment. Current Treatment Options in Neurology, 2024, 26, 97-114.	0.7	0
1396	Frontotemporal Dementia. , 2024, , .		0

#	Article	IF	Citations
1398	Neurodegenerative und Demenzielle Erkrankungen. , 2024, , 667-682.		0